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Abstract
Lynch Syndrome (LS), one of the most common hereditary cancer syndromes, is
primarily known for its substantially increased risks for colorectal cancer. The incidence
of gynecologic cancers (endometrial and ovarian cancers) equals or exceeds the incidence
of colorectal cancers in female patients with LS. The prevention and treatment methods
for these cancers can drastically affect fertility and reproduction. Previous studies with
cancer patients have revealed challenges in acquiring information related to these topics;
thus far, no research has assessed whether there is an informational gap regarding fertility
information for women in the LS population. The purpose of this study was to identify
the amount of information received related to fertility and reproduction, assess patient
satisfaction, and characterize current practices of this information delivery within our
target patient population.
Data was collected from 154 women with LS. Likert scales were used to quantify
the amount of information provided about major themes pertaining to fertility in LS:
effects of cancer treatment, risk-reducing surgeries, fertility preservation and family
planning. Overall, participants were more satisfied when they received more information
about certain topics within these themes. There was a distinct lack of individualization in
patient care, and lack of uniformity regarding the provision of this information among
healthcare providers. Participant opinions indicate that genetic counselors may be an
untapped resource in the provision of fertility and reproduction information to this
population.
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Chapter 1. Background
1.1 Lynch Syndrome
A hereditary cancer syndrome is characterized by the inheritance of a genetic
variant that predisposes its carrier to the development of cancers. Distinguishing features
of hereditary cancer syndromes include an early onset of cancers, the occurrence of
multiple primaries in a single individual, and several generations of affected individuals
within a family. These syndromes account for 5-10% of all cancer diagnoses, and
contribute to significant morbidity and mortality rates in the populations affected (Nagy,
2004). In order to reduce the clinical consequences, it is important to identify carriers
through appropriate screening programs and genetic testing (Robson, 2003).
Confirmation of a positive genetic diagnosis will detect at-risk individuals, justify
increased surveillance, aid in medical management, and help in the decision-making
concerning family planning and prophylactic interventions (Giardiello, 2014).
Lynch Syndrome (LS) is one of the most common hereditary cancer syndromes,
with an estimated population prevalence of 1 in 400 (Nagy, 2004). It is characterized by a
predisposition to a spectrum of cancers, but primarily known for its substantially
increased risks for colorectal and endometrial cancer. The history of this syndrome began
in the early 1900s when Dr. Aldred Warthin, a renowned pathologist, observed a pattern
of gastrointestinal and uterine cancers occurring frequently in a large family [“Family
G”] (Warthin, 1913). The medical records and family pedigrees in his study provided
some of the first evidence of the heritable nature of cancer susceptibility, a concept that at

1

the time was still under scrutiny. In the 1960s, Dr. Henry T. Lynch encountered two
families [“Family N” and “Family M”] that featured an extensive, multi-generational
history of early onset colorectal cancer, among other cancers; this cancer burden was
similar to the family described by Warthin (Lynch, 1966). After studying the collective
data from the three families, Lynch proposed that the presence of a syndromic disorder
was responsible for the cancer manifestation observed (Sehgal, 2014) and coined the
name ‘Cancer Family Syndrome’ in 1971. Due to the increased risk for colorectal cancer,
the condition was renamed Hereditary Nonpolyposis Colorectal Cancer (HNPCC) in
1984, which differentiated it from the other major inherited colorectal cancer syndrome,
Familial Adenomatous Polyposis. However, HNPCC was deemed a misnomer, as there is
a wide variety of extracolonic cancers associated with this syndrome, and was
subsequently renamed Lynch Syndrome (Cohen, 2014).
LS is an autosomal dominant condition that increases lifetime risks for colonic
and extracolonic cancers; the proposed risk values depend on the genetic variant inherited
in a family, and the sex and age of the affected individual (Tiwari, 2016). LS accounts for
2-4% of all colorectal cancers (CRC) (Barrow, 2013), and affected individuals have as
high as a 75% lifetime risk of developing CRC. The median age of diagnosis is between
44-61 years of age, with approximately 50% of all CRC tumors occurring below the age
of 50. This age of onset is 20-25 years earlier than the onset in sporadic cases of CRC,
which is typically at age 70 (Cohen, 2014). The progression of these CRC tumors exhibit
an accelerated carcinogenesis: small adenomas will develop into carcinomas within 2-3
years in LS patients, versus the 8-10 years in the general population. Other features of
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CRC in LS include the presence of synchronous and metasynchronous tumors, and an
increased incidence of tumors in the proximal colon (Lynch, 2009).
While CRC is a major clinical consequence in LS, affected individuals also have
substantial risks for extracolonic tumors. Female carriers of LS have a 15-61% risk for
developing endometrial cancer, which is much higher than the 1.7% risk of the general
population (Cohen, 2014; ACOG Practice Bulletin, 2014). The large risk range is due to
the fact that different genes confer differing risk values. Endometrial cancer in LS also
has an earlier age of onset at approximately 47-62 years, younger than the general
population’s typical age of onset at 70 (Cohen, 2014). LS accounts for 2% of all new
ovarian cancer diagnoses (Malander, 2006). The incidence of ovarian cancer in the
general population is 1.4%, but females with LS are at an increased risk for ovarian
cancer (approximately 6.7-12%), manifesting between the ages of 41-51 years (Cohen,
2014). Both male and female carriers have a 0.7-13% risk of developing gastric cancer,
which follows the trend of early onset. The lifetime risk for cancer of the urinary tract
(including the bladder, renal pelvis and ureter) ranges from 1.9-11.2%, again depending
on the genotype (Barrow, 2013). Individuals with LS are also at an elevated risk for
cancers of the hepatobiliary tract, small bowel, pancreas and CNS tumors. Furthermore,
there are variants of LS that are associated with specific cancer manifestations. MuirTorre syndrome was originally identified as a separate and distinct condition, but genetic
testing has proven its place on the LS spectrum. Muir-Torre syndrome is characterized by
a 9% risk for sebaceous neoplasms in addition to the other cancer risks in LS (South,
2008). The Turcot variant of LS features CNS tumors, particularly glioblastomas, in
additional to the elevated risk for other LS-associated cancers (Cohen, 2014).
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LS is caused by a germline mutation in one of the genes involved in the DNA
mismatch repair (MMR) pathway: MLH1, MSH2, MSH6, PMS2, or EPCAM. The
function of the MMR proteins is to proofread the DNA for the presence of base-pair
mismatches or small insertions or deletions introduced by replication error, and repair the
mistakes. A compromised MMR system will result in the accumulation of somatic
mutations, eventually leading to carcinogenesis (Cohen, 2014). In particular, defective
MMR will cause variations within the microsatellites of the DNA. Microsatellites are
short repetitive sequences within the genome; microsatellite instability (MSI) is a
hallmark of LS tumors and is frequently used for patient evaluation (Umar, 2004). It is
estimated that 80-90% of all LS cases are caused by deleterious mutation in MLH1 and
MSH2, and the remaining 10-20% of cases are due to MSH6 and PMS2 mutations
(Giardiello, 2014). Approximately 3% of cases are caused by mutations in the EPCAM
gene. Although EPCAM is not an MMR protein, certain mutations of EPCAM can lead to
epigenetic silencing of the MSH2, resulting in a LS phenotype (Kempers, 2011).
Genotype-phenotype correlations have been elucidated in LS. Individuals with
MLH1 and MSH2 mutations have the highest incidence risks and the widest array of
possible cancer manifestations. Mutations in MSH2 also has the highest risk for ovarian
cancer, approximately 8-12% lifetime risk (Chen, 2007; Bonadona, 2011). Carriers of the
MSH6 mutation have the highest risk for endometrial cancer, at 16-61% lifetime risk
(ACOG Practice Bulletin, 2014). The cancer risks for the PMS2 mutation carriers fall at
the lower end of the previously listed ranges, at 15% (Cohen, 2014). Due to the close
interaction between EPCAM and MSH2, individuals with an EPCAM mutation have
similar CRC risks as MSH2, but a reduced risk for endometrial cancer (Kempers, 2011).
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For healthcare providers, it is important to note that LS features differing rates of
penetrance depending on the genotype, and variable expressivity of cancers between
family members with the same mutation (Cohen, 2014).
Genetic testing for LS is recommended for individuals who meet specific clinical
and pathological guidelines. The original Amsterdam Criteria stipulated that in order to
qualify for a clinical diagnosis of LS, an individual would need to have at least three
family members affected with CRC, two successive generations of affected individuals,
and at least one diagnosis of CRC before the age of 50 (Vasen, 1991). However, this
criterion did not account for the extracolonic manifestations of LS and was later revised
to require a family history of “LS-associated cancers” instead of just CRC (Vasen, 1999).
The Revised Bethesda Guidelines were developed to identify patients at risk for LS who
did not meet the Amsterdam Criteria, and included a MSI evaluation and
immunohistochemical staining (IHC) the individual’s CRC or endometrial tumor. If a
biopsy was found to have a high load of MSI, it would raise suspicion for the presence of
a germline MMR mutation. An IHC assay screens for the present or absence of MMR
proteins in the tumor biopsies, which can indicate the presence of a germline mutation
(Umar, 2004).
Identification of individuals at-risk for LS through these screening modalities and
subsequent cascade testing is extremely important, as screening and preventative
measures can be taken to improve overall morbidity and mortality. At-risk individuals are
referred to genetic counseling for education about the medical, psychological, and
familial implications of the disorder, the commencement of genetic testing, and the
disclosure of the results (Vig, 2012). Once a diagnosis of LS is confirmed, there are
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detailed management protocols that can be implemented. The National Comprehensive
Cancer Network (NCCN) guidelines recommend increased surveillance for CRC through
annual colonoscopies. The commencement age for the colonoscopy does not differ by the
culprit gene: MLH1, MSH2, MSH6, PMS2 and EPCAM mutation carriers should begin at
20-25 years. Colonoscopies should begin 2-5 years prior to the earliest diagnosed CRC in
the family, and be repeated every 2-3 years. Screening for endometrial and ovarian
cancer can include annual endometrial sampling, serum CA-125 assays and transvaginal
ultrasound; however, there is no clear evidence supporting this screening, as the available
modalities do not have sufficient sensitivity or specificity. A prophylactic total abdominal
hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) is recommended as a
risk-reducing option after the completion of childbearing. There is no evidence
supporting screening for gastric and small bowel cancers, but select individual or families
may consider an esophagogastroduodenoscopy every 3-5 years beginning at 30-35 years.
An annual urinalysis beginning at 30-35 years will screen for cancers of the urinary tract.
A neurologic examination for CNS tumors can begin at 25-30 years. There are no
screening recommendations for cancers of the hepatobiliary tract and pancreas. Finally,
patients of reproductive age should be advised about options for prenatal diagnosis of LS
and assisted reproductive technologies (ART), as well as the risk for Constitutional
Mismatch Repair Deficiency syndrome (CMMRD) in offspring
2.2016).
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(NCCN, Version

1.2 Implications of Lynch Syndrome on Fertility
A diagnosis of LS can have significant implications on an individual’s fertility
and reproductive options. Individuals with LS are at a substantially increased risk for
developing early onset colorectal cancers. Treatment for CRC can include chemotherapy,
radiation therapy and surgical resection of the tumor. Different chemotherapeutic agents
will have different levels of gonadotoxicity. For example, adjuvant therapy with
fluorouracil (5-FU) will have little effect on fertility, but treatment with oxaliplatin may
cause irreversible premature ovarian failure (POF). Radiation therapy is commonly used
to treat rectal cancers, often given neoadjuvantly. The ovaries are extremely sensitive to
radiation, and the conventional cumulative dose of radiation will cause POF in most
women (Zbuk, 2009). Pelvic radiation can have obstetrical and neonatal consequences,
most notably increased rates of miscarriage, preterm labor, placental abnormalities and
low birthweight. These adverse outcomes are due to myometrial fibrosis, uterine
vasculature damage and endometrial injury (Wo, 2009). There may be inherent risks for
infertility associated with surgery for CRC. Postoperative adhesion formation in the
pelvis can alter the normal anatomic relationship between the uterine tubes and ovaries,
resulting in difficulties to conceive (Olsen, 2012).
A study conducted by Stupart et al. (2015) assessed the fertility rates of
unaffected MMR mutations carriers and affected carriers with a CRC diagnosis. For the
purposes of this study, “total fertility rates” was defined as the average number of
children a hypothetical cohort of affected women would have if they had children at the
population age-specific rate during their entire life. Total fertility for women with a CRC
diagnosis decreased by almost 40% in comparison to the unaffected group. While this
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appears to be a large reduction, the authors noted that the decision to have children is
influenced by many psychosocial factors. Nevertheless, cancer-related mortality and
morbidity, and effects of surgery and therapy can all be expected to play a role in the
decrease of fertility observed in women with CRC. It is also important to note that, while
fertility concerns may be incorporated as deciding factors, the exact management of CRC
should be tailored to each patient’s presentation, with the pros and cons of the chosen
treatments weighed accordingly (Zbuk, 2009).
The incidence of gynecologic cancers equals or exceeds the incidence of
colorectal cancers in female patients with LS (Mills, 2014). LS is responsible for a high
proportion of endometrial cancer cases diagnosed below the age of 45, approximately 912% (Dorais, 2011). In the treatment of gynecologic malignancies in young adults, the
interventions to spare fertility are concentrated on less radical surgery or a lower dose of
drug therapy to spare the reproductive organs as much as possible for subsequent fertility
(Lee, 2006). The standard treatment for endometrial cancer is a total abdominal
hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) with a retroperitoneal
lymphadenectomy (Dorais, 2011). Young women can pursue fertility-sparing options,
which entail a dilation and curettage of the lesion followed by non-gonadotoxic
chemotherapy or hormone management. The conservative approach to cancer treatment
is only available for low-grade tumors that are confined to the endometrium; any patient
who chooses this option must be informed of the risk of an undiagnosed synchronous or
metasynchronous endometrial tumor, and the increased risk for relapse (Bovicelli, 2012;
Hahn 2009). Alternately, immediate hysterectomy with ovarian conservation is another
option for patients who wish to attempt pregnancy using a gestational carrier. However,
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the rate of concurrent ovarian cancer in patients with premenopausal women with
endometrial cancer is approximately 11-29% (Evans-Metcalf, 1998). This is likely
exacerbated in women with Lynch Syndrome, whose baseline risk of ovarian cancer
increased above the general population. The type of treatment will depend on the type of
ovarian cancer, but the main treatment is surgery with debulking, with or without
chemotherapy. The feasibility of fertility sparing surgery as a treatment for ovarian
cancer is still hotly debated; this is especially due to the fact that ovarian cancer is the
most lethal gynecologic malignancy and the majority of women present in advanced
stages (Ditto, 2014; Raja, 2012).
While endometrial surveillance may be effective, the value of surveillance for
ovarian cancer is still under debate (Helder-Woolderink, 2016). The sensitivity and
specificity of CA-125 screening is known to be poor, and ultrasound detection has many
limitations, including the variation in result interpretation (Rauh-Hain, 2011). The most
effective means of reducing cancer mortality is through risk-reducing surgery (RRS).
Women with Lynch Syndrome are recommended to consider a total abdominal
hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) upon the completion of
childbirth (NCCN, Version 2.2016; Chapman, 2015). However, the temporal pressure to
pursue RSS has been shown to be a cause of anxiety in women of reproductive age. A
study by Donnelly et al. (2013) assessed reproductive decision-making in young women
who were carriers of a BRCA1/2 mutation; these mutations will predispose individuals to
increased risk for breast and ovarian cancer. That study found that these perceived
pressures caused distress in the patients and complicated social relationships. In addition,
a major disadvantage of a TAH-BSO is the early onset of menopause, which can have an
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increased risk of cardiovascular disease, loss of bone density, vaginal dryness, mood
disturbances, and reduced libido (Chapman, 2015).
The field of fertility preservation is rapidly expanding to include multiple
experimental and non-experimental options for female patients. Gonadal shielding during
radiation or ovarian transposition (oophoropexy) away from the radiation field can be
executed to reduce the amount of radiation damage to the ovaries. This technique,
however, does not protect the uterus from radiation damage. Embryo and oocyte
cryopreservation are established fertility preservation methods. These techniques require
ovarian stimulation and harvesting, which can delay therapy, and involve expensive costs
based on insurance coverage (Lee, 2006). Ovarian tissue cryopreservation is an
experimental option that does not require ovarian stimulation, but does involve a
laparoscopic procedure; it is a potential option for patients who need to urgently undergo
aggressive therapy (ASRM, 2014). Fertility preservation options each come with risks,
advantages and disadvantages. Interdisciplinary cooperation between surgeons,
oncologists, gynecologists, reproductive endocrinologists and other healthcare providers
is necessary for at-risk patients so that individualized options can be offered in advance
of or concurrently with surgery or adjunctive treatment (Spanos, 2008). Some individuals
may be concerned about the familial transmission of LS; due to the genetic nature of the
condition, patients have a 50% chance of passing on their MMR mutation to their
offspring. Prenatal diagnosis can be offered to expectant couples to determine the
mutation status of a pregnancy. Preimplantation genetic diagnosis (PGD), offered in
conjugation with an in vitro fertilization (IVF) cycle, allows for the identification of
embryos lacking the familial mutation to be selected for implantation (Simpson, 2016).

10

1.3 Informational Exchange between Healthcare Providers and Patients
Providing patients and their families with adequate information concerning
treatment and care is an ongoing challenge in most healthcare organizations. Kullberg et
al. (2015) sought to evaluate patients’ opinions on information provision in oncology
wards. This study used patient satisfaction to measure the quality of care as perceived by
the patients. Researchers concluded that there are deficits in the information exchange
between hospitalized cancer patients and healthcare staff, and that adequate information
is a prerequisite for patient participation in their own care. The issue of insufficient
information exchange can therefore affect many areas of a patient’s care. Finney Rutten
et al. (2016) found that individuals affected with cancer report challenges acquiring
information for decision-making throughout their care. This study found that information
seeking among cancer patients has increased from 66.8% in 2003 to 80.8% in 2013, and
is likely to continue increasing. Another important finding was that the most frequently
listed first sources of information were healthcare providers and the Internet. Deficits in
information exchange may be due to providers not rising to meet the increased
information needs of their patients. It has been previously observed that communication
difficulties exist in regards to fertility in cancer. In a recent study, participants reported
that oncology care and fertility care were provided independently of each other, leading
to fragmentation in both care and information provision (Goossens, 2015).
The American Society of Clinical Oncology (ASCO) states that oncologists are
responsible to inform patients about the possible risks for impaired fertility associated
with their cancer treatment and refer interested patients to reproductive specialists (Lee,
2006). However, Partridge et al. (2004) surveyed male and female cancer survivors of

11

reproductive age, and discovered that a least half have no memory of a discussion of
fertility at the commencement of their treatment. In the participants that did recall an
infertility discussion, most were dissatisfied with the quality and amount of information
provided. Another study by Strong et al. (2007) echoes a similar sentiment. This study
sought to quantify the incidence of fertility counseling in women of reproductive age
prior to treatment for colorectal cancer. Based on medical records, less than 20% of
women of reproductive age had documentation of counseling for post-treatment fertility.
An ASCO special article hypothesized reasons why oncologists may not disclose fertility
information: physicians are likely to prioritize discussions about immediate
complications of a cancer diagnosis instead of discussing the potential for infertility (Lee,
2006). If oncologists are not disclosing this information, it creates a knowledge gap for
patients. In some centers, a nurse specialist is able to fill this gap. Kelvin et al. (2016)
compared satisfaction with the amount of fertility-related information received between
reproductive-aged patients who did and did not receive counseling from a fertility clinical
nurse specialist. The study found that patients benefited from additional in-depth
counseling and education about fertility-related information. While the above evidence
listed is not specific to Lynch Syndrome, it is applicable to the care of patients with LS
due to their risk for early onset cancers that can influence their fertility. Oncologists and
other healthcare providers may be providing fertility-based information to LS patients
affected with cancer, but are likely not even in contact with presymptomatic carriers.
Genetic counseling is a recommended platform for the discussion of the cancer
risk and management options for patients diagnosed with a hereditary cancer syndrome.
The genetic counselor is equipped to comprehensively review the clinical consequences
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of Lynch Syndrome with both at-risk patients and newly diagnosed cancer patients. Few
other healthcare providers are involved with the discussion of risks for presymptomatic
carriers as well as those affected with an LS cancer. Presymptomatic carriers are a
population that can take advantage of increased surveillance, RRS and family planning.
Genetic counselors are also involved with conversations related to reproductive concerns
for this population, including the risk of transmission to offspring and the option of PGD
(Biesecker, 2001). Previous research has revealed that cancer genetic counselors consider
discussions of fertility preservation to be a part of their role (Volk, 2012). Goetsch et al.
(2016) found that reproductive endocrinologists utilize genetic counselors for the care of
individuals with an inherited cancer syndrome in regards to fertility preservation and
PGD. Therefore, genetic counselors have a role in the fertility-related care of individuals
with an inherited cancer syndrome, and may be the best resource to bridge the knowledge
gap in regard to fertility for patients with LS.

1.4 Fertility-Related Informational Needs in Hereditary Cancer Syndromes
Another common hereditary cancer syndrome is the Hereditary Breast and
Ovarian Cancer Syndrome (HBOC), a condition that is caused by mutations in the
BRCA1 and BRCA2 genes. Mutation carriers have greater than an 80% lifetime risk for
breast cancer and 40% risk for ovarian cancer by age 70 (Metcalfe, 2000). There have
been several studies that have evaluated fertility-related information concerns in the
BRCA1/2 mutation carrier population. Quinn et al. (2010) assessed the informational
needs of BRCA mutation carriers regarding issues of infertility and fertility options.
Participants in this study expressed a strong desire for assistance with decision-making
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and a need for better presentation of available fertility options. Another study by Kim et
al. (2015) evaluated patient knowledge of the clinical impact of a BSO and views of
fertility consultations in this patient population. It was noted that patients would benefit
from additional emphasis on fertility in all of their appointments with healthcare
providers, including genetic counseling. Studies in HBOC maybe generalizable to other
hereditary cancer syndromes, including LS. It may be a trend in hereditary cancer
syndromes that carriers need more accessible information regarding their fertility.
However, because there are different cancer risks between individuals with HBOC and
LS, there are different fertility concerns between these two populations. A practice
guideline released by the National Society of Genetic Counselors (NSGC) states that the
genetic counselor should include a provision of extensive client resources, including
information concerning fertility and reproductive choices, when counseling an individual
with a BRCA1/2 mutation (Berliner, 2012). There has not been a similar guideline
released in regards to LS.
In comparison to the extensive amount of data collected on the informational
needs of BRCA1/2 carriers, very few studies have investigated the needs of patients with
LS. It can be expected that a deficit of information also exists in LS, but there is little
research available on this topic. Using data collected from support groups for LS, a study
by Corines et al (2016) advocated that increased knowledge empowers patients with LS
to take a proactive role in their own health management. A previous study by Bannon et
al. (2014) examined the educational and information needs of individuals with LS, but
this assessment did not explore the informational needs related to fertility and
reproduction. Therefore, it is important to establish the exact informational needs of this

14

population in order for adequate information provision. Of note, a study by Burton-Chase
et al. (2017) found that LS CRC survivors reported lower levels of satisfaction with their
healthcare providers than sporadic CRC survivors, particularly in regard to
communication. This noted lack of satisfaction may exist broadly for individuals with LS.
Current studies regarding fertility and reproduction in patients with LS have only
examined the attitudes towards reproductive decision-making for childbearing, prenatal
genetic testing and assisted reproductive technologies (ART). Dewanwala et al. (2011)
compared patient attitudes towards childbearing and prenatal testing before and after
genetic testing for LS. This study’s findings suggest that individuals with LS are
interested in prenatal testing and PGD, and would consider having children earlier to
allow for earlier RRS. Duffour et al. (2015) reported distress among MMR mutation
carriers in regards to reproductive-decisions making, and increased interest in ART a year
after genetic testing. These two studies prove that women with Lynch Syndrome are
interested in the topics of fertility and reproduction, but they do not identify how and
when these topics are being presented to patients. Thus far, there have not been any
studies conducted that assess the need for information pertaining to the fertility
implications of Lynch Syndrome in the reproductive-aged patient population.
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Chapter 2. Assessment of Patient Satisfaction with the Provision of Fertility
Information in Women with Lynch Syndrome
2.1 Abstract
Lynch Syndrome (LS), one of the most common hereditary cancer syndromes, is
primarily known for its substantially increased risks for colorectal cancer. The incidence
of gynecologic cancers (endometrial and ovarian cancers) equals or exceeds the incidence
of colorectal cancers in female patients with LS. The prevention and treatment methods
for these cancers can drastically affect fertility and reproduction. Previous studies with
cancer patients have revealed challenges in acquiring information related to these topics;
thus far, no research has assessed whether there is an informational gap regarding fertility
information for women in the LS population. The purpose of this study was to identify
the amount of information received related to fertility and reproduction, assess patient
satisfaction, and characterize current practices of this information delivery within our
target patient population.
Data was collected from 154 women with LS. Likert scales were used to quantify
the amount of information provided about major themes pertaining to fertility in LS:
effects of cancer treatment, risk-reducing surgeries, fertility preservation and family
planning. Overall, participants were more satisfied when they received more information
about certain topics within these themes. There was a distinct lack of individualization in
patient care, and lack of uniformity regarding the provision of this information among
healthcare providers. Participant opinions indicate that genetic counselors may be an
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untapped resource in the provision of fertility and reproduction information to this
population.

2.2 Introduction
Lynch Syndrome (LS) is one of the most common hereditary cancer syndromes,
with an estimated population prevalence of 1 in 400 (Nagy, 2004). LS accounts for 2-4%
of all colorectal (CRC) cancers (Barrow, 2013) and affected individuals have as high as a
75% lifetime risk of developing CRC (Cohen, 2014). The median age of diagnosis is
between 44-61 years of age, with approximately 50% of all CRC tumors occurring below
the age of 50. Female carriers of LS have a 15-61% risk for developing endometrial
cancer, which is much higher than the 1.7% risk of the general population (Cohen, 2014;
ACOG Practice Bulletin, 2014). The incidence of ovarian cancer in the general
population is 1.4%, but females with LS are at an increased risk for ovarian cancer
(approximately 6.7-12%). Similar to CRC, both the endometrial and ovarian cancers in
LS manifest at earlier ages than the general population. Additional cancers associated
with Lynch Syndrome include the risk for gastric, urinary tract, hepatobiliary, pancreatic
and CNS.
The risk values for the colonic and extracolonic cancers depend on the genetic
variant inherited in a family, and the sex and age of the affected individual (Tiwari,
2016). LS is caused by a germline mutation in one of the genes involved in the DNA
mismatch repair (MMR) pathway: MLH1, MSH2, MSH6, PMS2, or EPCAM (Lynch,
2015). Individuals with MLH1 and MSH2 mutations have the highest incidence risks and
the widest array of possible cancer manifestations. Mutations in MSH2 also has the
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highest risk for ovarian cancer, approximately 8-12% lifetime risk (Chen, 2007;
Bonadona, 2011). Carriers of MSH6 mutations have the highest risk for endometrial
cancer, at 16-61% lifetime risk (ACOG Practice Bulletin, 2014). The cancer risks for the
PMS2 mutation carriers fall at the lower end of the previously listed ranges, at 15%
(Cohen, 2014). Due to the close interaction between EPCAM and MSH2, individuals with
an EPCAM mutation have similar CRC risks as MSH2, but a reduced risk for endometrial
cancer (Kempers, 2011). For healthcare providers, it is important to note that LS features
differing rates of penetrance depending on which gene is mutated, and variable
expressivity of cancers between family members with the same mutation (Cohen, 2014).
A diagnosis of Lynch Syndrome can have significant implications on a woman’s
fertility and reproductive options, particularly due to the incidence and early onset of
CRC, endometrial and ovarian cancers. Treatment for CRC can include chemotherapy,
radiation therapy and surgical resection of the tumor, all of which can disrupt the fertility
of a patient (Zbuk, 2009; Wo, 2009; Olsen, 2012). There are inherent risks for infertility
associated with surgery for CRC, as postoperative adhesion formation in the pelvis can
alter the normal anatomic relationship between the uterine tubes and ovaries, resulting in
difficulties to conceive (Olsen, 2012). A study conducted by Stupart et al. (2015)
assessed the fertility rates of unaffected MMR mutations carriers and affected carriers
with a CRC diagnosis: total fertility for women with a CRC diagnosis decreased by
almost 40% in comparison to the unaffected group. While there are many factors that
influence the decision to have children, the effects of surgery and therapy for CRC are
likely strong modifiers.
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The incidence of gynecologic cancers equals or exceeds the incidence of
colorectal cancers in female patients with LS (Mills, 2014). In the treatment of
endometrial malignancies in young women, the interventions to spare fertility are
concentrated on less radical surgery or a lower dose of drug therapy to spare the
reproductive organs as much as possible for subsequent fertility (Lee, 2006). Fertility
sparing options may be available for ovarian cancer, but its feasibility is still debated as
ovarian cancer is the most lethal gynecologic malignancy and the majority of women
present in advanced stages (Ditto, 2014; Raja, 2012).
While endometrial surveillance may be effective, the value of surveillance for
ovarian cancer is still disputed (Helder-Woolderink, 2016). The most effective means of
reducing gynecologic cancer mortality is through risk-reducing surgery (RRS), and
women with LS are recommended to consider a total abdominal hysterectomy with
bilateral salpingo-oophorectomy (TAH-BSO) upon the completion of childbirth (NCCN,
Version 2.2016). Choosing a TAH-BSO does come an array of disadvantages, including
the early onset of menopause (Chapman, 2015). Donnelly et al (2013) studied
reproductive decision-making in young patients with another hereditary cancer syndrome,
Hereditary Breast and Ovarian Cancer (HBOC), and found that the temporal pressures to
pursue RSS cause an increase in distress and social complications for the patient,
particularly in women who have not yet completed childbearing.
The field of fertility preservation can provide options for women in the LS
population; these options can offered in advance of or concurrently with surgery or
adjunctive treatment (Spanos, 2008). These options include gonadal shielding during
radiation, ovarian transposition, embryo cryopreservation, etc. (Lee, 2006; ASRM, 2014).
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Women with LS also have options for reproductive decision-making. Prenatal diagnosis
can be offered to expectant couples to determine the mutation status of a pregnancy.
Preimplantation genetic diagnosis (PGD), offered in conjugation with an in vitro
fertilization (IVF) cycle, allows for the identification of embryos lacking the familial
mutation to be selected for implantation (Simpson, 2016).
Interdisciplinary cooperation between healthcare providers is necessary to offer
individualized options to at-risk patients, but providing patients with adequate
information concerning treatment and care is an ongoing challenge. Finney Rutten et al.
(2016) found that individuals affected with cancer report challenges acquiring
information for decision-making throughout their care. These communication difficulties
certainly exist in regard to fertility and cancer. In a recent study, participants reported that
oncology care and fertility care were provided independently of each other, leading to
fragmentation in both care and information provision (Goossens, 2015). Kelvin et al.
(2016) compared satisfaction with the amount of fertility-related information received
between reproductive-aged patients who did and did not receive additional counseling
about fertility options. The study found that patients benefited from additional in-depth
counseling and education about fertility-related information.
The American Society of Clinical Oncology (ASCO) states that oncologists are
responsible to inform patients about the possible risks for impaired fertility associated
with their cancer treatment and refer interested patients to reproductive specialists (Lee,
2006). However, Partridge et al. (2004) surveyed male and female cancer survivors of
reproductive age, and discovered that a least half have no memory of a discussion of
fertility at the commencement of their treatment. In the participants that did recall an
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infertility discussion, most were dissatisfied with the quality and amount of information
provided. Another study by Strong et al. (2007) sought to quantify the incidence of
fertility counseling in women of reproductive age prior to treatment for colorectal cancer.
Based on medical records, less than 20% of women of reproductive age had
documentation of counseling for post-treatment fertility. An ASCO special article
hypothesized reasons why oncologists may not disclose fertility information: physicians
are likely to prioritize discussions about immediate complications of a cancer diagnosis
instead of discussing the potential for infertility (Lee, 2006). This hypothesis may be true
of other providers as well, such as gynecologists, reproductive endocrinologists, etc. If
healthcare providers are not disclosing this information, it creates an informational
disparity for patients.
Genetic counselors may be the best resource to bridge the knowledge gap in
regard to fertility for patients with LS. While oncologists and other healthcare providers
may be providing fertility-based information to LS patients affected with cancer, these
providers are likely not in contact with presymptomatic carriers, another group that
would benefit greatly by a discussion of the fertility risks in LS. Genetic counseling is a
recommended platform for the discussion of the cancer risk and management options for
patients diagnosed with a hereditary cancer syndrome, including presymptomatic carriers
and diagnosed cancer patients. They are equipped to manage conversations related to
reproductive concerns for this population, including the risk of transmission to offspring
and the option of preimplantation genetic diagnosis (PGD) (Biesecker, 2001). Previous
research has revealed that cancer genetic counselors consider discussions of fertility
preservation to be a part of their role (Volk, 2012). Goetsch et al. (2016) found that
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reproductive endocrinologists utilize genetic counselors for the care of individuals with
an inherited cancer syndrome in regards to fertility preservation and PGD. Increased
emphasis by genetic counselors on topics related to fertility may benefits patients.
However, there is a lot unknown about the current practices in fertility information
provision; characterization of current practices is necessary in order to consider the
implementation new techniques.
The available research regarding informational needs about fertility and
reproduction in LS is limited. However, there have been several studies that have
evaluated the fertility-related information concerns of individuals in the HBOC
population. Quinn et al. (2010) found a strong desire for assistance with decision-making
and a need for better presentation of available fertility options. Another study by Kim et
al. (2015) evaluated patient knowledge of the clinical impact of a prophylactic BSO and
views of fertility consultations in the HBOC population. It was noted that patients would
benefit from additional emphasis on fertility in all of their appointments with healthcare
providers, including genetic counseling. These studies indicate that, overall, there needs
to be a more focused provision of fertility information to mutation carriers in HBOC. It
can be expected this fertility-related information deficit also exists for patients with LS.
Current studies regarding fertility and reproduction in patients with LS have only
examined the attitudes towards reproductive decision-making for childbearing, prenatal
genetic testing and assisted reproductive technologies (Dewanwala, 2011; Duffour,
2015). The available research indicates that women with LS are interested in the topics of
fertility and reproduction, but thus far, no research has assessed the information gap
regarding fertility and reproduction information for this patient population. This study
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sought to evaluate the current practices of information delivery by identifying the amount
of information received on specific topics related to fertility and reproduction, assess
patient satisfaction of the disclosure of this information, and identify ways to establish a
more comprehensive care regimen for women with LS.

2.3 Materials and Methods
Study Population
This research study collected quantitative and qualitative data from women with
LS. From this population, both presymptomatic women and women affected with cancer
were invited to participate. However, individuals were required to meet specific
eligibility criteria in order to proceed with the questionnaire. The eligibility criteria
ensured that only the opinions of the targeted patient population would be captured by the
study. Participants must have been diagnosed with LS at a reproductive age, which for
the purposes of this study is defined as between the ages of 18-45. Participants were also
required to have a known pathogenic mutation in an MMR gene; pathogenic mutations
are clinically actionable, and would therefore warrant the initiation of an appropriate
management protocol. Additionally, there was specific exclusionary criteria: participants
with a recent diagnosis who have not returned for a follow-up appointment with their
healthcare provider were excluded from this study, as their initial appointment may not
have covered all of the relevant information to pertaining to their diagnosis with LS.
Males were also excluded from participating in the questionnaire, as the fertility concerns
for LS differ between men and women. Eligibility and ineligibility were determined by a
series of questions at the beginning of the survey; participants who were determined to be
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ineligible were skipped out of the questionnaire using the branch logic function of the
survey programming software provided by SurveyMonkey.com.
Survey Distribution
Participants were recruited by an invitational flyer (Appendixes A and B) to take
the online survey. The principle investigator contacted different online support
organizations for individuals with cancer via e-mail to request participation. The e-mail
request explained the purpose of the research study and asked for assistance in
distributing the invitation and link for the online survey to its members. The invitation
was distributed through the following organizations: the Hereditary Colon Cancer
Foundation, I Have Lynch Syndrome, Inc., Lynch Syndrome International, and the
Oncofertility Consortium. The participating organizations circulated the invitations
through e-mailing lists, websites, Facebook pages, Twitter, and other mediums of
communication. The survey link was issued between September and October 2016, and
was available for completion through December 15, 2016.
Instrumentation
For this research study, an original online survey was developed through
SurveyMonkey.com. The principle investigator constructed the questionnaire (Appendix
C), which was comprised of both quantitative and qualitative questions, following a
mixed methods research model. Quantitative questions were used to measure categorical
information about the participants, while the qualitative questions were used to provide
deeper insight into the participants’ experience in regard to fertility and LS. The
questionnaire consisted of a series of multiple choice, Likert scale, and free response
questions designed to assess the participant’s overall satisfaction with the fertility-related
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information given to them by their healthcare provider(s) upon or after their diagnosis of
LS. Within the questionnaire, definitions were provided for some of the terminology used
in order to promote participant comprehension. The consent agreement was provided on
the first page of the questionnaire (Appendix D); in order to move forward in the
questionnaire, participants needed to indicate their consent.
Standard demographic information obtained related to the participant’s current
age, gender, level of education, relationship status, country and region of residency, and
ethnicity. The survey also included questions specific to LS in order to further categorize
the participants: age at diagnosis, relationship status at the time of diagnosis, familial
MMR gene, and whether or not the participant was affected with cancer at the time of
their diagnosis. The demographic and categorical data provided variables for correlation
studies during the statistical analysis.
The rest of the questionnaire was divided into four sections, which each focused
on a different aspect of fertility concerns in LS: effects of cancer treatment, prophylactic
surgery, fertility preservation, and family planning. All four sections had a similar
composition of questions. Each section had a Likert scale, which aimed at assessing the
amount information provided about specific topics related to the section heading. Other
questions in the sections evaluated additional features of information provision, such as
the timing of the information provision and the healthcare provider involved. The final
question in each section assessed the participant’s overall satisfaction with the
information provided for the topics; this part of the questionnaire format was adapted
from a previous study by Kelvin et al. (2016). For this question, participants could select
whether they were “satisfied,” “not satisfied,” or “not interested” in the topics covered by
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that section. Participants also had the option of providing additional comments at the end
of every section. The last series of questions in the survey focused on the utility of
genetic counseling for fertility-related information provision for women with LS.
Data Analysis
Statistical analysis for the quantitative data was conducted using Statistical
Package for the Social Sciences 24.0 (SPSS). While the four main sections of the
questionnaire were analyzed independently of each other, the same analyses were
conducted for each section. The primary assessment focused on how the amount of
information provided about specific topics modified the satisfaction of the participants;
this analysis was conducted via one-way ANOVA. The amount of information provided
was quantified by calculating the average response to each item in the Likert scale
questions; the response of each item was coded 1 (“I received no information about this
topic”) through 5 (“I received a lot of information about this topic”).
A series of additional one-way ANOVAs were conducted to assess for association
between the amount of information provided and other modifying variables. The
variables were dichotomous to allow for comparisons: individuals affected with cancer
vs. presymptomatic carriers, individuals who had completed childbearing vs. those that
had not completed childbearing, and a comparison between the gene implicated in the
family. Chi-Square for association tests were conducted to assess overall satisfaction
between difference groups of participants. Pearson’s correlation and descriptive statistics
were used to evaluate the rest of the data, including demographic information, and
information collected about healthcare providers, and topics discussed by genetic
counselors.
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Responses to the open-ended questions were analyzed through inductive analysis,
and organized based on common themes. The themes were coded by the principle
investigator and reviewed by all authors. Participants’ responses to these questions were
brief and covered a limited range of topics; however, they offered valuable insight into
the personal experience of the participants.
In order to maximize the amount of data collected in this study, partially
completed surveys were included in the data analysis. Participants needed to have
completed at least two out of the four sections to be included in the analysis

2.4 Results
Eligibility
Of the 274 individuals that began the questionnaire, 172 met the eligibility
criteria. Ineligible participants included men (N=2), minors (N=2), individuals diagnosed
with LS after the age of 45 (N=62), individuals without a known pathogenic variant in an
MMR gene (or EPCAM) (N=14), and individuals who did not return to their healthcare
provider after their diagnosis (N=9). Of the 172 participants who met the eligibility
criteria, 18 individuals did not complete at least two of the four major sections within the
questionnaire. This resulted in a total of 154 participants who were both within our target
population and had completed at least half of the questionnaire.
Demographics
The demographic information for the participants in this study is depicted in
Table 2.1. The majority of women who participated in this study were between the ages
of 36-45 (40.2%), Caucasian (95.4%), married (72.0%), college-educated (43.8%), and
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living in the United States (85.4%). Almost half (46.1%) were diagnosed with LS
between the ages of 26-35. Participants were asked to report which gene was responsible
for their LS: MLH1 was reported by 28.6%, MSH2 by 44.8%, MSH6 by 13.6%, PMS2 by
11.7%, and EPCAM by 1.3%.
Most of the participants (61.7%, N=95) were presymptomatic at the time of their
diagnosis with LS, indicating that they had pursued predictive genetic testing (referred to
in this study as “presymptomatic carriers”). The remaining 38.3% (N=59) were
diagnosed with cancer before they were found to have LS (Table 2.2). Participants were
asked to report which cancer(s) they were diagnosed with: 58.8% reported colorectal
cancer, 19.1% reported endometrial cancer, 8.8% reported ovarian cancer, and 13.2%
selected “Other.” Those that selected “Other” reported a variety of cancers, including
breast, thyroid, and sebaceous carcinoma. Of note, many individuals reported multiple
cancers at early ages of onset, which is not unexpected within this patient population.
Participants were asked to report their status in family planning at the time of their
diagnosis with LS. Individuals who had completed their family prior to their diagnosis
accounts for 48.7% (N=75). The remaining 51.3% (N=79) had not yet completed their
family (Table 2.2).
Cancer Risks and Effects of Cancer Treatment
This section of the questionnaire collected data on the amount of information
provided to the participants about cancers risks and the effects of cancer treatment on
fertility. Skip logic was used to identify participants who have spoken with their
healthcare provider about the potential impacts of cancer treatment on fertility. Only
34.4% (N=53) of participants completed the corresponding section of the questionnaire.
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A one-way ANOVA was conducted to determine if the satisfaction status of the
participants was altered depending on the amount of information provided about a given
topic relating to cancer risks in LS and the effects of cancer treatment on fertility (Table
2.3). There was a trend towards statistical significance (p≤.05) for one topic (“The risk
for cancer will differ based on your gene”) [F(2, 50)=3.010, p=.058]: individuals who
received more information about this topic reported satisfaction with their experience.
A one-way ANOVA was conducted to identify whether or not there is a
difference in the amount of information provided about the topics in this section to
individuals that were affected with cancer at the time of their diagnosis with LS and
presymptomatic carriers with LS (Table 2.4). Statistically significant differences were
observed for one topic: “The risk for cancer will differ based on your gene” [F(1,
52)=4.828, p=.032]. Additionally, a trend toward statistical significance was noted for
“The effects of radiation on your reproductive organs” [F(1, 51)=3.513, p=.067]. For
these two topics, presymptomatic carriers received more information than individuals
affected with cancer.
A one-way ANOVA was conducted to establish whether there was a difference in
the amount of information provided between individuals who had completed their family
and those who had not completed their family at the time of their diagnosis with LS
(Table 2.5). There were no statistically significant findings observed.
A one-way ANOVA was conducted to examine whether or not there was a
difference in LS. There were no statistically significant findings observed.
In order to identify the healthcare providers involved in the provision of this
information, participants were provided a list of healthcare providers and asked to select
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the provider(s) who discussed with them information about cancer risk and the effects of
cancer treatment (Figure 2.1). The majority of participants selected oncologist (33.0%,
N=29), and the second most frequently selected provider was genetic counselor (24.0%,
N=21). Only 2.0% of participants (N=5) reported that no healthcare provider discussed
the information with them. Next, the participants were asked to select the healthcare
provider was most effective at discussing this information: 43.0% of individuals selected
oncologist and 26% selected genetic counselor.
Pearson’s correlation was run to assess the relationship between the timing of the
information and participant satisfaction. There was a statistically significant negative
correlation (r2=-.386, p=.004) between these variables: individuals who received
information about these topics greater than 6 months after their diagnosis with LS were
less satisfied.
Finally, participants were asked to share any comments they had about this
section of the survey. Many participants reported that the treatment of their cancer took
precedence over every other concern (N=8). One participant stated:
“I was more overwhelmed with my cancer diagnosis and cancer treatment.
(Treatment) was a priority, but more information (about the effects) would have
been nice.”
Others participants revealed that they would have preferred a more focused discussion
about the effects on cancer treatment on fertility (N=5):
“I would have preferred to have had more of a conversation about my options
with a specialist in fertility. I also would have liked follow up appointment/s posttreatment to assess if my fertility had been effected.”

30

Risk-Reducing Surgery
This section of the questionnaire collected data on the amount of information
provided to the participants about the risk-reducing surgical options for women with LS.
Skip logic was used to identify participants who have spoken with their healthcare
provider about risk-reducing surgeries. The majority of participants, 85.7% (N=132),
completed this part of the questionnaire. More than half (51.5%, N=68) reported that they
had some type of prophylactic surgery at the time of this questionnaire, and 58.8%
(N=40) of those participants were presymptomatic carriers.
A one-way ANOVA was conducted to determine if the satisfaction status of the
participants was altered depending on the amount of information provided about a given
topic relating to risk-reducing surgery options (Table 2.6). Statistically significant
differences were observed for five of six topics: “The timing of a risk-reducing
hysterectomy” [F(2, 128)=6.875, p=.001], “The timing of a risk-reducing oophorectomy”
[F(2,128)=9.617, p=.000], “My family history should be considered when planning for a
risk-reducing surgery” [F(2,127)=5.247, p=.006], “The side effects of a risk-reducing
oophorectomy before menopause” [F(2,128), p=.000], and “The option of a risk-reducing
hysterectomy with ovarian preservation” [F(2,128)=7.160, p=.001]. For these topics,
individuals who received more information about this topic reported satisfaction with
their experience.
A one-way ANOVA was conducted to identify whether or not there is a
difference in the amount of information provided about the topics in this section to
individuals that were affected with cancer at the time of their diagnosis with LS and
presymptomatic carriers with LS (Table 2.7). Statistically significant differences were
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observed for two topics: “The option of a risk-reducing hysterectomy with ovarian
preservation” [F(1, 130)=4.828, p=0.32], and “The use of birth control to reduce my
cancer risk” [F(1, 130)=4.183, p=.043]. For these two topics, presymptomatic carriers
received more information than individuals affected with cancer.
A one-way ANOVA was conducted to establish whether there was a difference in
the amount of information provided between individuals who had completed their family
and those who had not competed their family (Table 2.8). Statistically significant findings
were observed for two of the six topics: “The side effects of a risk-reducing
oophorectomy before menopause” [F(1, 130)=5.861, p=.017], and “The use of birth
control to reduce my cancer risk [F(1, 130)=9.473, p=.003]. For these topics, individuals
who had completed their families received more information than individuals who had
not completed their family.
A one-way ANOVA was conducted to examine whether or not there was a
difference in the amount of information provided to the participant based on the gene that
caused their LS. There were no statistically significant findings observed.
Participants were provided a list of healthcare providers and asked to select the
provider(s) who discussed with them information about risk reducing surgeries (Figure
2.2). The majority of participants selected gynecologist (35.0%, N=77), and the second
most frequently selected provider was genetic counselor (33.0%, N=73). Only 1% of
participants (N=3) reported that no healthcare provider discussed the information with
them. Next, the participants were asked to select the healthcare provider was most
effective at discussing this information: 41.0% of individuals selected gynecologist, while
37% selected genetic counselor.
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Pearson’s correlation was run to assess the relationship between the timing of the
information provision about risk-reducing surgeries and participant satisfaction. There
were no statistically significant findings.
Participants were asked to share any comments they had about this section of the
survey. One theme that emerged is that, prior to having a risk-reducing surgery, there was
very little discussion about post-surgery quality of life (N=11). Many individuals
reported that they felt that the symptoms of surgical menopause had not been adequately
communicated to them.
“I did not feel like I had enough information on menopause (or) hormone
replacement options instead (of surgery).”
Another theme was the pressure to pursue surgery (N=8). One participant shared:
“I guess I was made to feel that I didn't have much of a choice if I wanted to avoid
cancer. It was presented along the lines that there was no "reason to keep those
organs" since I was finished having children. I was made to feel that I was lucky
to have not been diagnosed with cancer so far, so (I should) have everything
removed immediately.”
Another participant said:
“I did not have cancer but consulted with a gynecologic oncologist. I could tell
she was unhappy with my decision to keep one ovary.”
Fertility Preservation
This section of the questionnaire collected data on the amount of information
provided to the participants about fertility preservation techniques. This section did not
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use the Skip Logic function used in the previous sections. Almost all of the participants
(97.4%, N=150) completed this section.
A one-way ANOVA was conducted to determine if the satisfaction status of the
participants was altered depending on the amount of information provided about a given
topic relating to fertility preservation (Table 2.9). Statistically significant differences
were observed for all four topics: “The option to shield or move the ovaries during
radiation therapy” [F(2, 140)=7.200, p=.001], “Embryo or egg cryopreservation
(freezing)” [F(2,140)=34.887, p=.000], “Ovarian tissue cryopreservation (freezing)”
[F(2,140)=14.606, p=.000], and “Ovarian stimulation will delay cancer treatment”
[F(2,140)=13.134, p=.000]. For these topics, individuals who received more information
about this topic reported satisfaction with their experience.
A one-way ANOVA was conducted to identify whether or not there is a
difference in the amount of information provided about the topics in this section to
individuals that were affected with cancer at the time of their diagnosis with LS and
presymptomatic carriers with LS (Table 2.10). There were no statistically significant
findings observed in this analysis.
A one-way ANOVA was conducted to establish whether there was a difference in
the amount of information provided between individuals who had completed their family
and those who had not completed their family at the time of their diagnosis with LS
(Table 2.11). Statistically significant findings were observed for all four topics: “The
option to shield or move the ovaries during radiation therapy” [F(1, 148)=4.375, p=.038],
“Embryo or egg cryopreservation (freezing)” [F(1, 148)=18.915, p=.000], “Ovarian
tissue cryopreservation (freezing)” [F(1, 148)=18.126, p=.000], and “Ovarian stimulation
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will delay cancer treatment” [F(1, 148)=8.017, p=.005]. For these topics, individuals who
had not completed their families received more information than those that had
completed their families.
A one-way ANOVA was conducted to examine whether or not there was a
difference in the amount of information provided to the participant based on the gene that
caused their LS. There were no statistically significant findings observed.
In order to identify the healthcare providers involved in the provision of this
information, participants were provided a list of healthcare providers and asked to select
the provider(s) who discussed with them information about fertility preservation (Figure
2.3). The most frequently selected healthcare provider was gynecologist (13.0%, N=21),
and the second was oncologist (9.0%, N=14). However, 63.0% of participants (N=102)
reported that no healthcare provider discussed the information with them. Next, the
participants were asked to select the healthcare provider was most effective at discussing
this information: there was no strong consensus, with 31.0% selecting oncologist, and
27.0% selecting gynecologist.
Pearson’s correlation was run to assess the relationship between the timing of the
information provision about fertility preservation and participant satisfaction. There were
no statistically significant findings.
The final question of this section was an open-ended question, requesting
participants to share any additional comments. Some participants reported that their
healthcare providers appeared to make assumptions about their interest in this type of
information (N=5). As one participant described:
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“My doctor was more apt to write off any preservation because I have two
children rather than being interested if we wanted anymore.”
Another subset of participants revealed that, due to the lack of information they received
from their healthcare providers, they had to research these topics themselves (N=7). One
participant acknowledged the inequality of the situation, saying:
“I was satisfied because I was a self advocate and did my own research. I met
another young woman who went through treatment a few months before me at the
same place, and she did not receive the information I did (because she didn't
initiate conversation). This is a huge problem; young women need to be told their
options.”
Family Planning
This section of the questionnaire collected data on the amount of information
provided to the participants about family planning options. This section did not have a
Skip Logic function. Again, almost all of the participants (90.3%, N=139) completed this
section.
A one-way ANOVA was conducted to determine if the satisfaction status of the
participants was altered depending on the amount of information provided about a given
topic relating to family planning (Table 2.12). Statistically significant differences were
observed for all six topics: “The chance that your children will have Lynch Syndrome”
[F(2, 130)=10.619, p=.001], “The use of an in vitro fertilization (IVF) cycle”
[F(2,130)=15.178, p=.000], “Prenatal diagnosis for Lynch Syndrome” [F(2,129)=10.284,
p=.000],

“Preimplantation

genetic

diagnosis

(PGD)

for

Lynch

Syndrome”

[F(2,129)=8.471, p=.000], “Adoption” [F(2,129)=9.762, p=.000], and “Surrogacy”
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[F(2,129)=9.688, p=.000]. For these topics, individuals who received more information
about this topic reported satisfaction with their experience.
A one-way ANOVA was conducted to identify whether or not there is a
difference in the amount of information provided about the topics in this section to
individuals that were affected with cancer at the time of their diagnosis with LS and
presymptomatic carriers with LS (Table 2.13). There was a trend towards statistical
significance for one topic: “The chance that your children will have Lynch Syndrome”
[F(1, 137)=3.496, p=.064]. For this topic, presymptomatic carriers received more
information than individuals affected with cancer.
A one-way ANOVA was conducted to establish whether there was a difference in
the amount of information provided between individuals who had completed their family
and those who had not completed their family at the time of their diagnosis with LS
(Table 2.14). Statistically significant findings were observed for all six topics: “The
chance that your children will have Lynch Syndrome” [F(1, 137)=15.145, p=.000], “The
use of an in vitro fertilization (IVF) cycle” [F(1, 137)=36.238, p=.000], “Prenatal
diagnosis for Lynch Syndrome” [F(1, 136)=18.022, p=.000], “Preimplantation genetic
diagnosis (PGD) for Lynch Syndrome” [F(1, 136)=18.487, p-.000], “Adoption” [F(1,
136)=21.716, p=.000], and “Surrogacy” [F(1, 136)=19.557, p=.000]. For these topics,
individuals who had not completed their families received more information than those
that had completed their families.
A one-way ANOVA was conducted to examine whether or not there was a
difference in the amount of information provided to the participant based on the gene that
caused their LS. One statistically significant finding was observed: individuals who
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reported having a mutation in the EPCAM gene received less information about these
topics than individuals with mutations in MSH1, MLH2, MSH6 and PMS2 [F(4,
134)=2.77, p=.030].
In order to identify the healthcare providers involved in the provision of this
information, participants were provided a list of healthcare providers and asked to select
the provider(s) who discussed with them information about fertility preservation (Figure
2.4). The most frequently selected healthcare provider was genetic counselor (29.0%,
N=47), and the second was gynecologist (9.0%, N=32). Approximately one third (32.0%,
N=51) of participants reported that no healthcare provider discussed the information with
them. Next, the participants were asked to select the healthcare provider was most
effective at discussing this information: 51% selected genetic counselor.
Pearson’s correlation was run to assess the relationship between the timing of the
information provision about family planning and participant satisfaction. There were no
statistically significant findings.
Finally, participants were asked to share any additional comments they had about
this section of the questionnaire. The major theme that emerged from this section is the
temporal pressure felt by the participants (N=7). One participant shared:
“My doctor basically told me if I want anymore children I needed to do it (as
soon as possible) then consider hysterectomy. That was all I was told.”
Overall Satisfaction
A chi-square test for association was conducted for overall reported satisfaction
between individuals who were affected with cancer at the time of their diagnosis and
presymptomatic carriers. No statistically significant findings were observed. However,
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there was a trend toward statistical significance for the section about risk-reducing
surgery options [χ2=4.852, p=.088]: individuals affected with cancer were overall more
satisfied then presymptomatic carriers with the information they received about these
topics.
A chi-square test for association was conducted for overall reported satisfaction
between individuals who had completed their families and individuals who had not
completed their families. There were statistically significant findings for three of the four
sections: individuals who had completed their family were more satisfied with the
information they received about cancer risks and the effects of cancer treatment on
fertility [χ2=15.998, p=.000], fertility preservation [χ2=20.612, p=.000], and family
planning [χ2=22.615, p=.000]. Additionally, a trend toward statistical significant was
observed for the other section: individuals who had completed their families were more
satisfied with the information they received about risk-reducing surgery options
[χ2=5.570, p=.062].
Genetic Counseling
The final section of the questionnaire focused on genetic counseling for LS, and
was completed by 133 individuals. The majority (81.9%, N=109) reported that they had
met with a certified or licensed genetic counselor. Participants were asked to select which
topic(s) were introduced to them by their genetic counselor from a list: cancer risk for LS,
effects of cancer treatment on fertility, risk-reducing surgeries for LS, fertility
preservation options, and family planning options. The most frequently selected topic
was cancer risks for LS (reported by 108 participants), followed by risk-reducing
surgeries for LS (N=89).
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Next, participants were asked to select which topics they would have wanted their
genetic counselor to provide more information about regarding their LS diagnosis. The
majority of individuals again selected cancer risks for LS and risk-reducing surgeries for
LS. There was, however, an increase in the amount of participants who selected the other
options (Figure 2.5).
Additional Comments
At the end of the questionnaire, participants were asked to share their final
comments about their experience with the topics covered by this research study. From
these comments, some important themes emerged. The first was the need for more a more
balanced conversation about the effects of cancer treatment on fertility and the aftermath
of a risk-reducing surgery (N=6). As one participant illustrated:
“Be more honest … It was all sunshine and "you're making the best choice; you
want to be around for your family." I felt very betrayed after surgery when I had
to deal with terrible hot flashes, bladder leakage, skin changes.”
Another theme was the psychological stress that comes with a lack of information about
their options with LS (N=10):
“There (were) no answers. Depression is the only definite outcome in Lynch
(syndrome).”

2.5 Discussion
This study explored the informational needs of women with LS. The focus of this
study was to assess patient satisfaction with the disclosure of information pertaining to
fertility and reproduction to women with LS, and to measure the amount of information
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provided about these topics to this patient population. Additionally, this research allows
us to evaluate the current practices of information delivery by identifying the healthcare
provider involved in patient education, timing in relation to diagnosis, and the topics of
this discussion. Analysis of these results can allow us to identify areas for improvement
in the care and management of women with LS.
Overall, participants were more satisfied with their experience when they received
more information. In the section of the questionnaire about cancer risk and the effects of
cancer treatment on fertility, we found statistical significance between the amount of
information provided and satisfaction for only one topic (“The risk for cancer will differ
based on your gene”). For the remaining four topics, the amount of information provided
did not affect satisfaction rates. This indicates that “The risk for cancer will differ based
on your gene” is an important topic to discuss with patients. In the sections about riskreducing surgery, fertility preservation and family planning, increased information was
associated with increased satisfaction for almost all of the covered topics, which suggests
that this information is important to patients, and therefore should be covered in detail by
a healthcare provider. Patient satisfaction is an extremely important part of healthcare,
and satisfaction is a proven measure of healthcare quality and success (Prakash, 2010).
Additionally, satisfaction has been positively correlated with adherence to screening and
treatment (Bredart, 2010). These findings prove that tangible changes in the amount of
information provided to a patient can alter their satisfaction and improve their healthcare
experience.
The Likert scales in this study were utilized to compare the amount of information
provided to different categories of participants, and assess the relationship between
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participant satisfaction and information provision. These measures also revealed that,
overall, participants did not receive a lot of information on these topics. Participants were
able to select a number 1 through 5 to designate the amount of information they received
on a specific topic, with 1 equating to “I received no information about this topic” and 5
equating to “I received a lot of information about this topic.” The calculated average of
the amount of information provided about the topics was 2.10. It is clear that participants
did not receive a lot of information about topics relating to fertility and reproduction.
This may indicate that the average patient is not aware of the plethora of options,
resources, and support available to them.
One initiative of this study was to identify whether there was a difference in the
amount of information provided to individuals who were affected with cancer at the time
of their Lynch syndrome diagnosis, and individuals who were presymptomatic at the time
of their diagnosis. For some topics in the sections about cancer risks and the effects of
cancer treatment, risk-reducing surgery, and family planning, we observed that
presymptomatic carriers received more information about certain topics than individuals
affected with cancer. The differences in information provision between these groups may
be due to the status of the patient at the time of their diagnosis: individuals with cancer
may have more pressing matters to discuss than fertility and reproductive information.
Nonetheless, these differences begs the question of whether or not there should be a
difference in the amount of information provided between these two subsets of the patient
population; as there are no available guidelines that direct providers to differentiate the
information they provided between these two subsets of patients, we should not have
observed this difference. For example, individuals who are affected with cancer have the
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same chance of transmitting LS to their current and future children; therefore, this
information is also essential for their overall care.
To further study the differences in the experience of individuals affected with
cancer and presymptomatic carriers, their overall satisfaction levels were compared
across the four sections. There was a trend towards statistical significance for the riskreducing surgery section. Overall, individuals who were affected with cancer were more
satisfied than the presymptomatic carriers. This may indicate an increased need for
healthcare providers to emphasize the risk-reducing surgery options during their
discussions with that category of patients.
Another initiative of this study was to evaluate the differences in the amount of
information provided to individuals who had completed their families at the time of their
diagnosis with Lynch syndrome, and those who had not completed their families. While
there were no differences noted in the section about cancer risk and the effects of cancer
treatment on fertility, there were statistical findings observed in the other three sections.
For the risk-reducing surgery section, we found that individuals who had completed their
families received more information about these topics than the other group. It is not
unexpected that individuals who have completed their family are receiving more
information on risk-reducing surgeries, as the NCCN guidelines (NCCN, 2.2016)
recommends that all women consider a TAH-BSO after completion of childbearing. It
may be that women who are past childbearing are in a life stage where they are ready for
such information; however, more research is needed to investigate this difference. In the
sections about fertility preservation and family planning, individuals who had not
completed their families received more information about these topics than those that had
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finished their families. This is a positive finding, as family planning topics are more
applicable to individuals who have not completed their families. These results show that
the discussion of family planning seems to be targeted to the appropriate individuals.
We compared the overall satisfaction rates over the four sections of this
questionnaire between individuals who had completed their families and those that had
not. Overall, individuals who had completed their families were more satisfied with their
experience than individuals who had not completed their families. Combined with the
prior results, this indicates that although individuals who have not completed their
families are receiving more information about these topics, they are not satisfied with
their experience. This study has identified areas of dissatisfaction, though more research
is needed to determine why patients are dissatisfied. Possible explanations may be that
the quality of information is insufficient. Another explanation may be that the
information is not being individualized to the patient. One participant noted that the
doctor did not discuss information about fertility preservation because she already had
children; healthcare providers may be generalizing their discussion and not taking the
individual concerns of their patients into account.
Our participants’ reported gene frequencies did not match up to the expected
percentages. Many studies quote the percentages listed by Lynch and de la Chappelle
(2003), who stated that MLH1 and MSH2 account for 90% of reported variants, and
MSH6 accounts for the majority of the remaining cases. In our study, MLH1 and MSH2
variants comprised only 73.4% (28.6% and 44.8%, respectively). MSH6 was reported by
13.6% of participants, PMS2 by 11.7%, and EPCAM by 1.3%. Interestingly, there was
essentially no statistically significant difference in the amount of information provided to
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participants based on their reported gene. Our one significant finding, that individuals
with EPCAM mutation received less information about family planning options, is not
generalizable, as there were only two participants with EPCAM mutation in our study.
There are different cancer risks at different ages depending on the gene that is
causing LS. For example, individuals with an MSH2 mutation have the highest risk for
ovarian cancers (Bonadona, 2011); one would assume that these participants should be
receiving a lot of information on fertility and reproduction. The current NCCN guidelines
do not differentiate screening or RSS recommendations based on the patient’s genotype;
our results show that healthcare providers are following those guidelines, as all of our
participants were receiving similar amounts of information, regardless of genotype.
However, with clear differences reported on the cancer risks per gene and with this study
reporting a need for individualization based on the patient, it may be time for professional
societies to re-evaluate their recommendations for the care and management of
individuals with LS. Indeed, other studies have echoed our findings. Bonadona et al.
(2011) noted that while TAH-BSO should be considered for women with MLH1 or
MSH2, the role of gynecological surgery for MSH6 carriers is debatable. Cohen et al.
(2014) suggested that it is important to incorporate gene- and age-specific data to provide
the most comprehensive care of patients with LS. Thus far, gene-specific guidelines have
not been released from any professional organizations.
The timing of information provision can often play a critical role in a patient’s
healthcare experience. In our study, we found a negative correlation between timing and
satisfaction for the section about cancer risks and the effects of cancer treatment on
fertility: individuals who received this information greater than six months after their
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diagnosis were less satisfied. This is a reasonable finding, as cancer treatment is often
enacted swiftly, and receiving information about these topics a long period of time after a
diagnosis could limit the options available to a patient. For the other three sections, there
were no significant findings about the relationship between timing and information
provision. This suggests that it may not be necessary to discuss certain topics during the
initial diagnosis, but that some topics may be presented in the several months following a
patient’s diagnosis with LS.
In this study, we requested that participants report the healthcare provider who
was involved with the provision of information regarding the topics in the four sections.
An oncologist, a gynecologist and a genetic counselor were the providers that were most
often selected, which indicates that these three providers are most often involved in this
information provision; therefore, those providers should be aware of their responsibility
in this matter, and ensure that they are discussing this information to their patients, or
referring the patients to another provider that can manage this role.
Notably, in the fertility preservation section, a large percentage (63.0%) of
participants indicated that no healthcare provider discussed those topics with them. This
is a major issue, as a lack of discussion about these topics creates an informational gap
for patients. In regard to fertility preservation, ASCO stated that oncologists are
responsible to discuss possible risks of impaired fertility and refer interested patients to
reproductive specialists (Lee, 2006); ACOG does not have specific recommendations
about these topics in regard to LS (ACOG Practice Bulletin, 2014). Since these two
providers were most often selected as the source of discussions about fertility
preservation by our participants, these providers should either be equipped for discussion
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of these topics, or equipped to make an appropriate referral. Research by Volk et al.
(2012) revealed that cancer genetic counselors consider discussions of fertility
preservation to be a part of their role. Therefore, a referral to a genetic counselor may be
an appropriate avenue to eliminate this informational gap.
Additionally, we found that 32.0% of participants reported that no healthcare
provider discussed with them topics relating to family planning. The current NCCN
guidelines recommend that patients be informed about inheritance risk, prenatal diagnosis
and ART options (NCCN, 2.2016). ASCO and ACOG do not have any guidelines
regarding the discussion of family planning in patients with LS (Lee, 2006; ACOG
Practice Bulletin, 2014). However, inheritance risk and others topics in this section are
often featured in genetic counseling sessions for hereditary cancer syndromes. Again, this
finding provides support to the expanded use of genetic counselors in the care of these
patients.
Participants were also able to select the provider whom they thought was most
effective at discussing this information. In three of the four sections (cancer risk and
effects of cancer treatment, risk-reducing surgery options, and family planning), a
substantial percentage of participants selected genetic counselor. Again, this implies that
there is a need for expansion of the genetic counselor’s role in regard to the provision of
this information. As previously stated, genetic counselors may take on the responsibility
to make sure the above topics are effectively communicated to their patients (Goetsch,
2016; Volk, 2012; Biesecker, 2011). Increased emphasis by genetic counselors on topics
related to fertility and reproduction may provide benefit to patients. Additionally, genetic
counselors are trained in resource awareness, and would be able to bridge an
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informational gap for a patient by identifying options for a patient to access this
information.
To further study the genetic counseling appointments for our participants, we
asked which topics pertaining to fertility and reproductive information were discussed by
their genetic counselor. Individuals could select topics from a list that represented the
main subjects covered in this questionnaire. The most frequently selected subjects were
“cancer risk for Lynch syndrome” and “risk-reducing surgeries for Lynch syndrome.”
However, when asked which topics participants would have wanted their genetic
counselor to discuss, many individuals selected the other available topics (“effects of
cancer treatment on fertility”, “fertility preservation options”, and “family planning
options”) in addition to those two topics. These findings may indicate an increased
patient interest in an expansion of the topics covered by a genetic counselor in regard to
fertility and reproductive information, which is a sentiment echoed in the previous
paragraph.
The qualitative aspects of this study allowed for a more in depth understanding of
the participants’ experience. First, many participants voiced the need for more a focused
fertility consultation. This may be accomplished through a referral to a fertility specialist,
or from appropriate delivery of this information from the healthcare provider involved
with the patient’s care. Additionally, participants felt pressured to pursue risk-reducing
surgeries, and this pressure appeared be exacerbated by a lack of information about these
surgeries and the potential side effects. Some participants reported completing their own
research on these topics because healthcare providers did not readily discuss those topics
with them. A number of participants who had chosen to pursue a risk-reducing surgery
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stated that they were not adequately warned about the onset of menopause. And finally,
lack of information or answers about one’s future with LS can cause significant
psychological stress, which can negatively impact many aspects of one’s life. Many of
these reported issues can be ameliorated by increased information provision and targeting
this provision to the appropriate patients.
Limitations
There are some limitations to consider when evaluating this study. First, there was
a clear lack of diversity within our study participants. The majority of participants were
married, educated Caucasians who fit into a narrow sociodemographic band, which
reduces our ability to generalize this study’s results to all women with LS. Second,
participants were asked to recall the content of discussions that had occurred, in some
cases, many years ago. The responses in retrospective studies such as ours may not be
entirely accurate due to the chance for inaccurate recall. The topics selected for inclusion
in this study did not encompass all of the available topics about fertility and reproduction
in LS; for example, participants were not asked about the information they received about
the chance for CMMRD in their offspring. Since the NCCN guidelines recommend
discussion of the chance for CMMRD in patients with LS, future research on this subject
should include information about that topic. Another limitation is that our participant
population was acquired through online support groups, which can introduce a sampling
bias. While this is a limitation, it also adds an interesting layer to our results as
individuals who participate in support groups are generally “information-seekers”. Our
study shows that these information-seekers are not getting a lot of information from their
healthcare providers about fertility and reproductive concerns in LS. Finally, for our
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ANOVA analyses, we did not meet the assumption of homogeneity of variance,
indicating that there may be better modes of analyses that could be applied to our dataset.
Research Recommendations
This study has revealed new data about the informational needs regarding fertility
and reproductive information for women with LS, and provides a number of
opportunities for future research. Conducting a qualitative study on this subject matter
would allow for a more in-depth understanding of the participants’ experience, and also
provide information about the quality of the discussion on these topics, rather than just
the quantity of information provided. Our study focused on the patient’s perspective of
their healthcare experience; it would be interesting to conduct this study using
oncologists, gynecologists and genetic counselors as a participant population. Research
into how the healthcare providers present this information, the extent of detail they
include, the types of referrals they make, and the types of patients they target will reveal
the healthcare providers’ perspective, and may also identify flaws in current practice.
Finally, the development of specific education tools for the distribution of information
relating to fertility and reproduction for women with LS may help to eliminate the
informational gap in knowledge for this patient population.

2.6 Conclusions
This study sought to provide insight to the needs of women with LS in respect to
information about fertility and reproduction. By surveying this patient population, we
were able to evaluate the current practices of this information delivery and identify areas
for improvement. Our results establish that this type of information is important to
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women with LS, and its appropriate provision can contribute to a patient’s overall
satisfaction with their healthcare experience. However, patients are not receiving a large
amount of information regarding the topics covered in this study, which can lead to a
decreased in patient awareness of the options, resources, and support available to them.
This lack of comprehensive information provision can also increase their perceived
psychosocial stress.
Our results also reveal two seemingly conflicting recommendations: the need for
uniformity and the need for individualization. It is essential that we create a more
uniform strategy for the provision of this information to this patient population.
Guidelines should be created identifying the extent of and type of information that should
be provided, and the healthcare providers that should be involved with this process.
However, it is also crucial that this information be individualized to fit the patient’s
specific needs. In particular, the information provided must to be tailored to the patient’s
age, current status in regard to cancer burden and family planning, and, most importantly,
their genotype.
Finally, this research implies a need for expansion of the genetic counselor’s role
in the provision of fertility and reproductive information for women with LS. Participants
identified genetic counselors as the most effective healthcare provider to discuss these
topics, and genetic counselors are well equipped to manage the discussion, counseling
and referral process associated with this subject matter. Increased emphasis by genetic
counselors on topics related to fertility and reproduction may present a way to eliminate
the knowledge gap for women with LS. Overall, this study has contributed to our
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understanding of the perspectives of women with LS, and has provided strategies to
promote more comprehensive care of this patient population.
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Table 2.1 Participant Demographic Information
Individual Participant

N

(%)

Current Age
18-25 years
26-35 years
36-45 years
>46 years

N=154
6
58
62
28

(3.9)
(37.7)
(40.2)
(18.2)

Age at LS Diagnosis
<18 years
18-25 years
26-35 years
36-45 years

N=154
2
20
71
61

(1.3)
(13.0)
(46.1)
(39.6)

Gene

N=154
44
69
21
18
2

(28.6)
(44.8)
(13.6)
(11.7)
(1.3)

MLH1
MSH2
MSH6
PMS2
EPCAM
Highest Education
Some High School
High School/GED
Some College
Associate’s Degree
Bachelor’s Degree
Some Graduate School
Graduate Degree

N=130
0
8
22
9
57
7
27

(0)
(6.2)
(16.9)
(6.9)
(43.8)
(5.4)
(20.8)

Individual Participant

N

(%)

Country of Origin1
Australia
Canada
New Zealand
Norway
Sweden
United Kingdom
United States

N=123
6
5
1
1
1
4
105

(4.9)
(4.1)
(0.8)
(0.8)
(0.8)
(3.2)
(85.4)

Region of the United States
Northeast2
Southeast3
Midwest4
Southwest5
Rocky Mountain6
Pacific7

N=105
27
16
28
11
6
17

(25.7)
(15.2)
(26.7)
(10.5)
(5.7)
(16.2)

Ethnicity
American Indian/Native
Asian/Pacific Islander
Black/African Am.
Hispanic or Latino
White/Caucasian

N=132
3
0
0
3
126

(2.3)
(0)
(0)
(2.3)
(95.4)

Relationship Status
Married
Widowed
Divorced
Separated
In a Domestic Partnership
In a Relationship
Single, Never Married

N=154
111
0
6
1
4
23
9

(72.0)
(0)
(4.0)
(0.6)
(2.6)
(15.0)
(5.8)

1

Participants were able to choose from a pre-populated list of 154 countries
Includes ME, VT, NH, MA, CT, NY, RI, PA, NJ
3
Includes DE, MD, DC, VA, WV, NC, SC, KY, TN, FL, GA, AL, MS, AR, LA
4
Includes OH, IN, IL, MI, WI, MN, IA, MO, ND, SD, NE, KS
5
Includes OK, TX, NM, AZ
6
Includes CO, UT, WY, MT, ID, NV
7
Includes WA, OR, CA, HI, AK
2

Table 2.2 Additional Participant Characteristics
N

Individual Participant
Which best describes your health status at the time of your diagnosis with LS?
I was diagnosed with cancer, then discovered I have LS.
I had genetic testing and discovered I have LS.
Which best describes your family status at the time of your diagnosis with LS?
I had completed my family/ I was not interested in having children.
I had not completed my family.
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N=154
59
95
N=154
75
79

(%)
(38.3)
(61.7)
(48.7)
(51.3)

Table 2.3 Amount of Information Provided and Participant Satisfaction: Cancer
Risks and the Effects of Cancer Treatment
Cancer Risks
and Effects of
Cancer
Treatment
The risk for cancer will
differ based on your
gene.
The risk for cancer will
differ based on your age.
The effects of
chemotherapy on your
reproductive organs.
The effects of radiation
on your reproductive
organs
The effects of surgery for
CRC on your ability to
conceive a pregnancy.

N

Not Satisfied
Mean
SD

N

Satisfied
Mean

df

F

pvalue

SD

17

2.53

1.77

29

2.41

1.80

(2, 50)

3.10

0.058

17

2.53

1.77

29

3.31

1.87

(2, 49)

0.95

0.393

17

2.00

1.80

29

2.76

1.97

(2, 49)

0.85

0.433

17

1.65

1.90

29

2.03

2.17

(2, 49)

0.29

0.753

17

1.53

1.46

28

2.36

2.04

(2, 49)

1.60

0.212

Table 2.4 Information Provision between Individuals Affected with Cancer vs.
Presymptomatic Carriers: Cancer Risks and the Effects of Cancer Treatment
Cancer Risks
and Effects of
Cancer
Treatment
The risk for cancer will
differ based on your
gene.
The risk for cancer will
differ based on your age.
The effects of
chemotherapy on your
reproductive organs.
The effects of radiation
on your reproductive
organs
The effects of surgery for
CRC on your ability to
conceive a pregnancy.

Affected with Cancer
N
Mean
SD

N

df

F

pvalue

35

2.54

1.93

19

3.68

1.60

(1, 52)

4.83

0.032

34

2.76

1.89

19

3.63

1.74

(1, 51)

2.71

0.106

34

2.47

2.08

19

2.42

1.57

(1, 51)

0.01

0.928

34

1.47

2.11

19

2.53

1.68

(1, 51)

3.51

0.067

34

1.76

1.83

19

2.26

1.85

(1. 51)

0.89

0.348
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Presym. Carrier
Mean
SD

Table 2.5 Information Provision between Individuals who have Completed their
Family vs. Individuals who have not Completed their Family: Cancer Risks and
Effects of Cancer Treatment
Cancer Risks
and Effects of
Cancer
Treatment
The risk for cancer will
differ based on your
gene.
The risk for cancer will
differ based on your age.
The effects of
chemotherapy on your
reproductive organs.
The effects of radiation
on your reproductive
organs.
The effects of surgery for
CRC on your ability to
conceive a pregnancy.

Completed Family
N
Mean
SD

Not Completed Family
N
Mean
SD

df

F

pvalue

33

2.64

1.98

21

3.43

1.66

(1, 52)

2.32

0.134

32

3.09

1.96

21

3.05

1.77

(1, 51)

0.01

0.931

32

2.19

1.84

21

2.86

1.96

(1, 51)

1.60

0.212

32

1.53

1.95

21

2.33

2.06

(1, 51)

2.05

0.158

32

1.75

1.81

21

2.24

1.87

(1, 51)

0.89

0.348

Table 2.6 Amount of Information Provided and Participant Satisfaction: RiskReducing Surgery
Risk-Reducing
Surgery
The timing of a riskreducing hysterectomy.
The timing of a riskreducing oophorectomy.
My family history should
considered when
planning for a riskreducing surgery.
The side effects of a riskreducing oophorectomy
before menopause.
The option of a riskreducing hysterectomy
with ovarian
preservation.
The use of birth control
to reduce my cancer risk.

N
60

Not Satisfied
Mean
SD
3.42
1.39

N
67

Satisfied
Mean
SD
3.98
1.49

df

F

pvalue

(2, 128)

6.88

0.001

60

2.80

1.63

67

3.85

1.64

(2, 128)

9.62

0.000

59

2.97

1.65

67

3.63

1.75

(2, 127)

5.25

0.006

60

2.10

1.31

67

3.64

1.60

(2, 128)

23.03

0.000

60

1.78

1.30

67

2.79

1.91

(2, 128)

7.16

0.001

60

1.90

1.64

67

1.93

2.00

(2, 128)

1.17

0.314

55

Table 2.7 Information Provision between Individuals Affected with Cancer vs.
Presymptomatic Carriers: Risk-Reducing Surgery
Risk-Reducing
Surgery
The timing of a riskreducing hysterectomy.
The timing of a riskreducing oophorectomy.
My family history should
considered when
planning for a riskreducing surgery.
The side effects of a riskreducing oophorectomy
before menopause.
The option of a riskreducing hysterectomy
with ovarian
preservation.
The use of birth control
to reduce my cancer risk.

Affected with Cancer
N
Mean
SD
45
3.51
1.80

N
87

Presym. Carrier
Mean
SD
3.74
1.36

df

F

pvalue

(1, 130)

0.64

0.424

45

3.24

1.94

87

3.33

1.65

(1, 130)

0.08

0.783

45

2.98

2.09

86

3.42

1.54

(1, 129)

1.88

0.173

45

3.00

1.92

87

2.73

1.57

(1, 130)

0.78

0.378

45

1.69

1.95

87

2.61

1.53

(1, 130)

8.87

0.003

45

1.44

1.86

87

2.13

1.79

(1, 130)

4.18

0.043

Table 2.8 Information Provision between Individuals who have Completed their
Family vs. Individuals who have not Completed their Family: Risk-Reducing
Surgery
Risk-Reducing
Surgery
The timing of a riskreducing hysterectomy.
The timing of a riskreducing oophorectomy.
My family history should
considered when
planning for a riskreducing surgery.
The side effects of a riskreducing oophorectomy
before menopause.
The option of a riskreducing hysterectomy
with ovarian
preservation.
The use of birth control
to reduce my cancer risk.

Completed Family
N
Mean
SD
72
3.79
1.64

Not Completed Family
N
Mean
SD
60
3.50
1.37

df

F

pvalue

(1, 130)

1.20

0.275

72

3.62

1.83

60

2.93

1.59

(1, 130)

5.05

0.026

72

3.28

1.91

59

3.25

1.56

(1, 129)

0.01

0.939

72

3.14

1.72

60

2.43

1.60

(1, 130)

5.86

0.017

72

2.42

1.90

60

2.15

1.52

(1, 130)

0.77

0.381

72

1.46

1.76

60

2.42

1.81

(1, 130)

9.47

0.003
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Table 2.9 Amount of Information Provided and Participant Satisfaction: Fertility
Preservation
Fertility
Preservation
The option to shield or
move the ovaries during
radiation therapy.
Embryo or egg
cryopreservation.
Ovarian tissue
cryopreservation.
Ovarian stimulation will
delay cancer treatment.

N
65

Not Satisfied
Mean
SD
0.92
1.08

N
27

Satisfied
Mean
SD
1.07
1.75

df

F

pvalue

(2, 140)

7.20

0.001

65

1.22

1.33

27

2.81

2.09

(2, 140)

34.89

0.000

65

0.85

0.67

27

1.41

1.76

(2, 140)

14.60

0.000

65

0.92

0.95

27

1.60

2.10

(2, 140)

13.13

0.000

Table 2.10 Information Provision between Individuals Affected with Cancer vs.
Presymptomatic Carriers: Fertility Preservation
Fertility
Preservation
The option to shield or
move the ovaries during
radiation therapy.
Embryo or egg
cryopreservation.
Ovarian tissue
cryopreservation.
Ovarian stimulation will
delay cancer treatment.

Affected with Cancer
N
Mean
SD
56
0.78
1.53

N
94

Presym. Carrier
Mean
SD
0.66
0.78

df

F

pvalue

(1, 148)

0.44

0.507

56

1.39

1.99

94

1.06

1.31

(1, 148)

1.49

0.224

56

0.70

1.19

94

0.76

0.86

(1, 148)

0.12

0.727

56

0.96

1.61

94

0.69

0.90

(1, 148)

1.77

0.185

Table 2.11 Information Provision between Individuals who have Completed their
Family vs. Individuals who have not Completed their Family: Fertility Preservation
Fertility
Preservation
The option to shield or
move the ovaries during
radiation therapy.
Embryo or egg
cryopreservation.
Ovarian tissue
cryopreservation.
Ovarian stimulation will
delay cancer treatment.

Completed Family
N
Mean
SD
85
0.54
1.07

Not Completed Family
N
Mean
SD
65
0.92
1.15

df

F

pvalue

(1, 148)

4.38

0.038

85

0.72

1.23

65

1.80

1.81

(1, 148)

18.92

0.000

85

0.45

0.75

65

1.11

1.15

(1, 148)

18.13

0.000

85

0.55

1.05

65

1.11

1.35

(1, 148)

8.02

0.005
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Table 2.12 Amount of Information Provided and Participant Satisfaction: Family
Planning
Family Planning
The chance that your
children will have Lynch
syndrome.
The use of an in vitro
fertilization (IVF) cycle.
Prenatal diagnosis for
Lynch syndrome.
Preimplantation genetic
diagnosis (PGD) for
Lynch syndrome.
Adoption.
Surrogacy.

N
55

Not Satisfied
Mean
SD
3.56
1.61

N
39

Satisfied
Mean
SD
4.41
1.39

df

F

pvalue

(2, 130)

10.62

0.000

55

1.71

1.54

39

2.43

2.10

(2, 130)

15.72

0.000

55

1.69

1.54

38

2.03

1.92

(2, 129)

10.28

0.000

55

1.67

1.56

38

1.87

2.04

(2, 129)

8.47

0.000

55
55

1.33
1.25

1.35
1.28

38
38

1.37
1.29

1.48
1.56

(2, 129)
(2, 129)

9.76
9.68

0.000
0.000

Table 2.13 Information Provision between Individuals Affected with Cancer vs.
Presymptomatic Carriers: Family Planning
Family Planning
The chance that your
children will have Lynch
syndrome.
The use of an in vitro
fertilization (IVF) cycle.
Prenatal diagnosis for
Lynch syndrome.
Preimplantation genetic
diagnosis (PGD) for
Lynch syndrome.
Adoption.
Surrogacy.

Affected with Cancer
N
Mean
SD
53
3.11
2.07

Presym. Carrier
N
Mean
SD
86
3.72
1.72

df

F

pvalue

(1, 137)

3.49

0.064

53

1.47

1.97

86

1.52

1.61

(1, 137)

0.03

0.866

52

1.27

1.73

86

1.49

1.55

(1, 136)

0.59

0.442

52

1.21

1.68

86

1.43

1.65

(1, 136)

0.56

0.455

52
52

0.90
1.06

1.43
1.65

86
86

1.09
0.89

1.20
0.97

(1, 136)
(1, 136)

0.69
0.53

0.407
0.468

Table 2.14 Information Provision between Individuals who have Completed their
Family vs. Individuals who have not Completed their Family: Family Planning
Family Planning
The chance that your
children will have Lynch
syndrome.
The use of an in vitro
fertilization (IVF) cycle.
Prenatal diagnosis for
Lynch syndrome.
Preimplantation genetic
diagnosis (PGD) for
Lynch syndrome.
Adoption.
Surrogacy.

Completed Family
N
Mean
SD
79
2.97
2.07

Not Completed Family
N
Mean
SD
60
4.17
1.33

df

F

pvalue

(1, 137)

15.14

0.000

79

0.81

1.33

60

2.42

1.82

(1, 137)

38.24

0.000

78

0.92

1.44

60

2.03

1.63

(1, 136)

18.02

0.000

78

0.85

1.39

60

2.00

1.76

(1, 136)

18.49

0.000

78
78

0.60
0.56

0.98
0.99

60
60

1.57
1.47

1.44
1.41

(1, 136)
(1, 136)

21.72
19.56

0.000
0.000
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Cancer Risks and Effects of Cancer Treatment1
Which healthcare provider was most effective at discussing this
information with you?
20

35
30
25
20
15
10
5
0

# Reported

# Reported

Which healthcare provider discussed the effects of cancer
treatment on fertility with you? (Check all that apply)

15
10
5
0

Onc. Gyn.

Onc. Gyn.

RE Nurse GC Other No
One
Healthcare Provider

RE Nurse GC Other
Healthcare Provider

1

The following abbreviations were used for this chart: Onc. (Oncologist), Gyn. (Gynecologist), RE (Reproductive Endocrinolgist), and
GC (Genetic Counselor). Additionally, the selection of “No One” indicates that no healthcare provider discussed these topics with the
participant.

Figure 2.1 Healthcare Providers: Cancer Risks and Effects of Cancer Treatment
Risk-Reducing Surgery1
Which healthcare provider was most effective at discussing this
information with you?

100

60

80

50
# Reported

# Reported

Which healthcare provider discussed risk-reducing surgery
options with you? (Check all that apply)

60
40
20

40
30
20
10
0

0
Onc. Gyn.

RE

Nurse GC

Other

Onc.

No
One

Gyn.

Healthcare Provider

RE

Nurse

GC

Other

Heatlhcare Provider

1

The following abbreviations were used for this chart: Onc. (Oncologist), Gyn. (Gynecologist), RE (Reproductive Endocrinologist),
and GC (Genetic Counselor). Additionally, the selection of “No One” indicates that no healthcare provider discussed these topics with
the participant.

Figure 2.2 Healthcare Providers: Risk-Reducing Surgery
Fertility Preservation1
Which healthcare provider was most effective at discussing this
information with you?

120
100
80
60
40
20
0

20
# Reported

# Reported

Which healthcare provider discussed fertility preservation
options with you? (Check all that apply)

15
10
5
0

Onc. Gyn. RE Nurse GC Other No
One

Onc.

Gyn.

RE

Nurse

GC

Other

Healthcare Provider

Healthcare Provider
1

The following abbreviations were used for this chart: Onc. (Oncologist), Gyn. (Gynecologist), RE (Reproductive Endocrinologist),
and GC (Genetic Counselor). Additionally, the selection of “No One” indicates that no healthcare provider discussed these topics with
the participant.

Figure 2.3 Healthcare Providers: Fertility Preservation
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Family Planning1
Which healthcare provider was most effective at discussing this
information with you?

60
50
40
30
20
10
0

# Reported

# Reported

Which healthcare provider discussed family planning options
with you (Check all that apply)

Onc. Gyn.

40
35
30
25
20
15
10
5
0
Onc.

RE Nurse GC Other No
One
Healthcare Provider

Gyn.

RE

Nurse

GC

Other

Healthcare Provider

1

The following abbreviations were used for this chart: Onc. (Oncologist), Gyn. (Gynecologist), RE (Reproductive Endocrinologist),
and GC (Genetic Counselor). Additionally, the selection of “No One” indicates that no healthcare provider discussed these topics with
the participant.

Figure 2.4 Healthcare Providers: Family Planning
Which topics were introduced to you by your genetic counselor about your Lynch
Syndrome diagnosis? (Check all that apply)
Family Planning Options

Topic

Fertility Preservation Options
Risk-Reducing Surgeries for Lynch Syndrome
The Effects of Cancer Treatment on Fertility
Cancer Risks for Lynch Syndrome
0

50

100

150

# Reported
Which topics would you want your genetic counselor to give you more
information about your Lynch Syndrome diagnosis? (Check all that apply)
Family Planning Options

Topic

Fertility Preservation Options
Risk-Reducing Surgeries for Lynch Syndrome
The Effects of Cancer Treatment on Fertility
Cancer Risks for Lynch Syndrome
0

20

40

# Reported

Figure 2.5 Genetic Counseling for LS

60

60

80

Chapter 3. Conclusions
This study sought to provide insight to the needs of women with LS in respect to
information about fertility and reproduction. By surveying this patient population, we
were able to evaluate the current practices of this information delivery and identify areas
for improvement. Our results establish that this type of information is important to
women with LS, and its appropriate provision can contribute to a patient’s overall
satisfaction with their healthcare experience. However, patients are not receiving a large
amount of information regarding the topics covered in this study, which can lead to a
decreased in patient awareness of the options, resources, and support available to them.
This lack of comprehensive information provision can also increase their perceived
psychosocial stress.
Our results also reveal two seemingly conflicting recommendations: the need for
uniformity and the need for individualization. It is essential that we create a more
uniform strategy for the provision of this information to this patient population.
Guidelines should be created identifying the extent of and type of information that should
be provided, and the healthcare providers that should be involved with this process.
However, it is also crucial that this information be individualized to fit the patient’s
specific needs. In particular, the information provided must to be tailored to the patient’s
age, current status in regard to cancer burden and family planning, and, most importantly,
their genotype.
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Finally, this research implies a need for expansion of the genetic counselor’s role
in the provision of fertility and reproductive information for women with LS. Participants
identified genetic counselors as the most effective healthcare provider to discuss these
topics, and genetic counselors are well equipped to manage the discussion, counseling
and referral process associated with this subject matter. Increased emphasis by genetic
counselors on topics related to fertility and reproduction may present a way to eliminate
the knowledge gap for women with LS. Overall, this study has contributed to our
understanding of the perspectives of women with LS, and has provided strategies to
promote more comprehensive care of this patient population.
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Appendix A. Invitational Flyer
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Appendix B. Facebook Post
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Appendix C. Survey Questionnaire
Important Definitions
Lynch Syndrome
Lynch Syndrome is an inherited condition that is characterized by an increased
risk for early onset cancers, including colorectal, endometrial, ovarian and gastric
cancers. The genes that cause Lynch Syndrome are MLH1, MSH2, MSH6, PMS2,
and EPCAM.
Fertility
Fertility is the ability to naturally conceive and carry a pregnancy.
Gender
1.) What is your gender?
Male
Female
Other
Prefer not to say
Age
2.) What is your current age?
Below 18 years old
18-25 years old
26-35 years old
36-45 years old
46 years or older
3.) How old were you when you were diagnosed with Lynch Syndrome?
Below 18 years old
18-25 years old
26-35 years old
36-45 years old
46 years or older
Participant Details
4.) Based on your genetic testing results, which gene was found to have a disease-causing
change?
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MLH1
MSH2
MSH6
PMS2
EPCAM
I do not recall
I have a variant of unknown significance
5.) Did you return to a healthcare provider for a follow-up appointment after your
diagnosis with Lynch Syndrome?
Yes
No
6.) Select the situation that best applies to you.
I was diagnosed with cancer, and afterwards I was found to have Lynch
Syndrome
I pursued genetic testing and found that I have Lynch Syndrome
Other (please specify)
7.) What cancer were you diagnosed with? (Check all that apply)
Colon cancer
Rectal cancer
Endometrial cancer
Ovarian cancer
Gastric cancer
Urinary Tract cancer
Other cancer (please specify)
8.) Please list your age at the diagnosis of each cancer (Example: Colon, 26;
Endometrial, 44)

9.) Which of the following best describes your current relationship status?
Married
Widowed
Divorced
Separated
In a domestic partnership or civil union
In a relationship
Single, never married
Other (please specify)
10.) Which of the following best describes your relationship status at the time of your
diagnosis with Lynch Syndrome?
Married
Widowed
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Divorced
Separated
In a domestic partnership or civil union
In a relationship
Single, never married
Other (please specify)
11.) Which of the following best describes your status at the time of your diagnosis with
Lynch Syndrome?
I was done with childbearing because I had completed my family
I had not yet completed my family
I had not yet started a family but planned to have children in the future
I was not interested in having children
Other (please specify)
Cancer and Cancer Treatment
12.) Did your provider discuss with you the impact of potential cancer treatment (such as
chemotherapy) on fertility?
Yes
No
(page break)
13.) Which topics were discussed with you about the effects of cancer treatment on
fertility? (1- I received no information on this topic, 5- I received a lot of information on
this topic)
1

2

3

The risk of
cancer will
differ based
on your gene.
The risk of
cancer will
differ based
on your age.
The effects of
chemotherapy
on your
reproductive
organs.
The effects of
radiation on
your
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4

5

Not
Applicable

reproductive
organs.
The effects of
surgery for
colorectal
cancer on
your ability to
conceive a
pregnancy.
14.) Approximately how long after your diagnosis with Lynch Syndrome did you receive
information about the effects of cancer treatment on fertility?
I received this information when I received my diagnosis
I received this information within a month after my diagnosis
One month after my diagnosis
Six months after my diagnosis
One year after my diagnosis
More than one year after my diagnosis
I did not receive this information
I do not recall
Other (please specify)
(page break)
15.) Which healthcare provider discussed the effects of cancer treatment on fertility with
you?
Oncologist
Gynecologist
Reproductive Endocrinologist
Nurse/Nurse Specialist
Genetic Counselor
No healthcare provider discussed this information with me
Other (please specify)
16.) Which healthcare provider was most effective at discussing this information with
you?
A drop down menu of the above options
17.) What informational resources were provided to you on these topics?
A referral to a fertility specialist or reproductive endocrinologist
An informational pamphlet or fact sheet
A website
A book
A support group
I was not provided any resources about this topic
Other (please specify)
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18.) Which resource was most helpful?
A drop box menu of the above options
19.) Were you satisfied with the amount of information you received about the effects of
cancer treatment on your fertility?
I was satisfied with the amount of information I received
I was not satisfied because I did not receive enough information
I was not satisfied because I did not receive any information
I was not interested in receiving this type of information
20.) Please share any additional comments you have.

Risk-Reducing Surgery and Other Alternatives
21.) Did your provider discuss with you the impact of risk-reducing surgeries (such as a
hysterectomy) on fertility?
Yes
No
Important Definitions
The following definitions will be helpful for the next section of this questionnaire:
Risk-Reducing Surgery
Surgery to reduce the risk of having cancer (also known as prophylactic surgery).
Hysterectomy
Surgery to remove the uterus
Oophorectomy
Surgery to remove one or both of the ovaries
Hysterectomy with Ovarian Preservation
Surgery to remove the uterus but keep, or preserve, one or both of the ovaries.
(page break)
22.) Have you had any of the following surgeries because of your diagnosis with Lynch
Syndrome? (Check all that apply)
Risk-Reducing Hysterectomy
Risk-Reducing Oophorectomy
No, I have not had a risk-reducing surgery
Other (please specify)
(page break)
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23.) Which topics were discussed with you about risk-reducing surgery for Lynch
Syndrome? (1- I received no information on this topic, 5- I received a lot of information
on this topic)

24.) Approximately how long after your diagnosis with Lynch Syndrome did you receive
information about risk-reducing options?
I received this information when I received my diagnosis
I received this information within a month after my diagnosis
One month after my diagnosis
Six months after my diagnosis
One year after my diagnosis
More than one year after my diagnosis
I did not receive this information
I do not recall
Other (please specify)
(page break)
25.) Which healthcare provider discussed information about risk-reducing options with
you?
Oncologist
Gynecologist
Reproductive Endocrinologist
Nurse/Nurse Specialist
Genetic Counselor
No healthcare provider discussed this information with me
Other (please specify)
26.) Which healthcare provider was most effective at discussing this information with
you?
A drop down box of the above options
27.) What informational resources were provided to you on these topics?
A referral to a fertility specialist or reproductive endocrinologist
An informational pamphlet or fact sheet
A website
A book
A support group
I was not provided any resources about this topic
Other (please specify)
28.) Which resource was most helpful?
A drop down box of the above options
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29.) Were you satisfied with the amount of information you received about risk-reducing
options for Lynch Syndrome?
I was satisfied with the amount of information I received
I was not satisfied because I did not receive enough information
I was not satisfied because I did not receive any information
I was not interested in receiving this type of information
30.) Please share any additional comments you have.

Fertility Preservation
The following definitions will be helpful for the next section of this questionnaire:
Risk-Reducing Surgery
Surgery to reduce the risk of having cancer (also known as prophylactic surgery).
Hysterectomy
Surgery to remove the uterus.
Oophorectomy
Surgery to remove one or both of the ovaries.
Hysterectomy with Ovarian Preservation
Surgery to remove the uterus but keep, or preserve, one or both of the ovaries.
31.) Which topics were discussed with you about fertility preservation options? (1- I
received no information on this topic, 5- I received a lot of information on this topic)
1
2
3
4 5
Not
Applicable
The option
to shield or
move the ovaries
during radiation
therapy.
Embryo or egg
cryopreservation
(freezing).
Ovarian tissue
cryopreservation
(freezing).
Ovarian
stimulation will
delay cancer
treatment.
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32.) Approximately how long after your diagnosis with Lynch Syndrome did you receive
information about fertility preservation?
I received this information when I received my diagnosis
I received this information within a month after my diagnosis
One month after my diagnosis
Six months after my diagnosis
One year after my diagnosis
More than one year after my diagnosis
I did not receive this information
I do not recall
Other (please specify)
(page break)
33.) Which healthcare provider discussed information about fertility preservation options
with you?
Oncologist
Gynecologist
Reproductive Endocrinologist
Nurse/Nurse Specialist
Genetic Counselor
No healthcare provider discussed this information with me
Other (please specify)
34.) Which healthcare provider was most effective at discussing this information with
you?
A drop down box of the above options
35.) What informational resources were provided to you on these topics?
A referral to a fertility specialist or reproductive endocrinologist
An informational pamphlet or fact sheet
A website
A book
A support group
I was not provided any resources about this topic
Other (please specify)
36.) Which resource was most helpful?
A drop down menu of the above options
37.) Were you satisfied with the amount of information you received about fertility
preservation?
I was satisfied with the amount of information I received
I was not satisfied because I did not receive enough information
I was not satisfied because I did not receive any information
I was not interested in receiving this type of information
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38.) Please share any additional comments you have.

Family Planning
39.) Which topics were discussed with you about family planning options? (1- I received
no information on this topic, 5- I received a lot of information on this topic)
1

2

3.

4

5

Not
Applicable

The chance that
your children
will have
Lynch
Syndrome.
The use of an
in vitro
fertilization
(IVF) cycle.
Prenatal
diagnosis of
Lynch
Syndrome.
Preimplantation
genetic
diagnosis
(PGD) for
Lynch
Syndrome.
Adoption.
Surrogacy
40.) Approximately how long after your diagnosis with Lynch Syndrome did you receive
information about family planning options?
I received this information when I received my diagnosis
I received this information within a month after my diagnosis
One month after my diagnosis
Six months after my diagnosis
One year after my diagnosis
More than one year after my diagnosis
I did not receive this information
I do not recall
Other (please specify)
(page break)
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41.) Which healthcare provider discussed this information with you?
Oncologist
Gynecologist
Reproductive Endocrinologist
Nurse/Nurse Specialist
Genetic Counselor
No healthcare provider discussed this information with me
Other (please specify)
42.) Which healthcare provider was most effective at discussing this information with
you?
A drop down menu of the above options
43.) What informational resources were provided to you on these topics?
A referral to a fertility specialist or reproductive endocrinologist
An informational pamphlet or fact sheet
A website
A book
A support group
I was not provided any resources about this topic
Other (please specify)
44.) Which resource was most helpful?
A drop down menu of the above options
45.) Were you satisfied with the amount of information you received about family
planning options?
I was satisfied with the amount of information I received
I was not satisfied because I did not receive enough information
I was not satisfied because I did not receive any information
I was not interested in receiving this type of information
46.) Please share any additional comments you have.

Genetic Counseling for Lynch Syndrome
47.) Have you previously met with a certified or licensed genetic counselor (CGC,
LGC)?
Yes
No
Not Sure
48.) Which topics were introduced to you by your genetic counselor about your
Lynch Syndrome diagnosis? (Check all that apply)
Cancer Risks for Lynch Syndrome
The Effects of Cancer Treatment on Fertility
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Risk-Reducing Surgeries for Lynch Syndrome
Fertility Preservation Options
Family Planning Options
49.) Which topics would you want your genetic counselor to give you more
information about your Lynch Syndrome diagnosis? (Check all that apply)
Cancer Risks for Lynch Syndrome
The Effects of Cancer Treatment on Fertility
Risk-Reducing Surgeries for Lynch Syndrome
Fertility Preservation Options
Family Planning Options
50.) Please share any additional comments you have.

Additional Demographic Information
51.) What is the highest level of education that you have completed?
Some High School
High School or GED
Some College
Associate’s Degree
Bachelor’s Degree
Some Graduate School
Graduate School (Master’s, PhD, MD, JD, etc.)
52.) In what country do you currently reside in?
A drop down menu of countries is provided for this question.
53.) What is your ethnicity?
American Indian or Alaskan Native
Asian or Pacific Islander
Black or African American
Hispanic or Latino
White/Caucasian
Prefer not to answer
Other (please specify)
54.) Which U.S. region do you currently reside in?
Northeast (ME, VT, NH, MA, CT, NY, RI, PA, NJ)
Southeast (DE, MD, DC, VA, WV, NC, SC, KY, TN, FL, GA, AL, MS, AR,
LA)
Midwest (OH, IN, IL, MI, WI, MN, IA, MO, ND, SD, NE, KS)
Southwest (OK, TX, NM, AZ)
Rocky Mountain (CO, UT, WY, MT, ID, NV)
Pacific (WA, OR, CA, HI, AK)
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Drawing Information
All participants are invited to enter a drawing for a $25 Visa gift card. If you are
interested, please select "Yes." You will be guided to a page that requests your name and
email contact. Your contact information will not be used for any other purposes beyond
sending you the gift card if you have won.
55.) Are you interested in entering a drawing to win a $25 Visa gift card?
Yes
No
Please provide your name and email contact.
Name
Email Contact

Please follow the link below for access to the online survey:
https://www.surveymonkey.com/r/Preview/?sm=K8ch01rRedrDI7s8ioFRr_2BqnkVBgp5
R1zjvZoRP4Bbo_3D
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Appendix D. Participant Consent Agreement
We would like to invite women with Lynch Syndrome to participate in a study about the
delivery of fertility information. The purpose of this study is to understand how
information about fertility issues is presented to women with Lynch Syndrome. We will
ask you about your satisfaction of your experience with this topic.
Your participation would be greatly appreciated, as your opinions will increase our
understanding of the specific needs of women with Lynch Syndrome We believe that the
results of this study will contribute to better presentation of fertility information to
patients, the creation of more thorough practice guidelines, and increased consistency in
the care of this patient population.
Your participation in the study is voluntary, and you can withdraw from the study at any
time. Participating in the study involves the completion an online survey. The survey is
anonymous, meaning that we will not collect any personal information that could identify
you or connect you to your responses. However, if you are interested in being entered
into a raffle for a $25 Visa gift card, you can include your name and contact information
at the end of the survey. Your contact information will not be used for any other purposes
beyond sending you the raffle prize if you have won. This survey should take
approximately 15 minutes to complete. Questions in the survey will ask you about your
satisfaction of the delivery and presentation of fertility-related information, the healthcare
providers involved, the resources that you received, and demographic information about
yourself.
This study is being conducted by Rachel Hickey, a genetic counseling student at the
University of South Carolina Medical School for a Master’s Thesis project. Emily
Jordon, a genetic counselor at the University of South Carolina, is the faculty thesis
advisor for this study. If you have any questions about this study, please contact us.
Rachel Hickey, B.S.
University of South Carolina
2 Medical Park, Suite 103
Columbia, SC 29203

Emily Jordon, M.S., C.G.C.
University of South Carolina
2 Medical Park, Suite 103
Columbia, SC 29203

Rachel.hickey@uscmed.sc.edu

Emily.jordon@uscmed.sc.edu

For questions about your rights as a participant, you may contact the Office of Research
Compliance at the University of South Carolina at (803) 777-7095.
By clicking the “Next” button below, you are indicating your consent to participate in
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this study.
Thank you for sharing your insight.

84

